[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 198
1. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR: Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer; 2010 Nov 1;116(21):5038-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer.
  • BACKGROUND: The risk of developing brain metastases after definitive treatment of locally advanced nonsmall cell lung cancer (NSCLC) is approximately 30%-50%.
  • The risk for patients with early stage disease is less defined.
  • The cumulative incidence of brain metastases and distant metastases was estimated by using the Kaplan-Meier method.
  • A multivariate analysis assessed factors associated with the development of brain metastases.
  • RESULTS: Of 975 consecutive patients, 85% were stage I, and 15% were stage II.
  • The 5-year actuarial risk of developing brain metastases and distant metastases was 10%(95% confidence interval [CI], 8-13) and 34%(95% CI, 30-39), respectively.
  • Of patients developing brain metastases, the brain was the sole site of failure in 43%.
  • On multivariate analysis, younger age (hazard ratio [HR], 1.03 per year), larger tumor size (HR, 1.26 per cm), lymphovascular space invasion (HR, 1.87), and hilar lymph node involvement (HR, 1.18) were associated with an increased risk of developing brain metastases.
  • CONCLUSIONS: In this large series of patients treated surgically for early stage NSCLC, the 5-year actuarial risk of developing brain metastases was 10%.
  • A better understanding of predictive factors and biological susceptibility is needed to identify the subset of patients with early stage NSCLC who are at particularly high risk.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cranial Irradiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Recurrence. Risk Factors


2. Matsuda Y, Tanaka T, Sato S, Kitamura H, Takahashi S, Masumori N, Tsukamoto T: [Clinical features of patients with brain metastasis from testicular germ cell tumor]. Hinyokika Kiyo; 2010 Feb;56(2):99-102
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of patients with brain metastasis from testicular germ cell tumor].
  • Five (2.6%) of them had brain metastasis.
  • The clinical stage was III in all the patients, except one with stage I disease.
  • Two patients had brain metastasis at the initial presentation.
  • As local therapies for brain metastases, surgical resection was done in 4 and gamma knife was in 1.
  • Whole brain irradiation was added to surgery in 2 patients.
  • All patients died of the disease within one year after brain metastasis development, except 1 patient who was free of disease 47 months after the presentation.
  • The long survivor had solitary brain metastasis at the initial presentation and received 4 regimens of chemotherapy, 2 surgical resections of brain metastases and whole brain irradiation.
  • Finally, chemotherapy consisting of irinotecan and nedaplatin resulted in normalization of the tumor markers and complete remission was proved by the subsequent surgical resection.
  • Although most patients with brain metastasis have a poor clinical outcome, aggressive local treatment and employment of novel anticancerous agents may contribute to improve clinical course of selected patients with germ cell tumors and brain metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185995.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 7673326042 / irinotecan; 8UQ3W6JXAN / nedaplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Lavado A, Oliver G: Prox1 expression patterns in the developing and adult murine brain. Dev Dyn; 2007 Feb;236(2):518-24
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prox1 expression patterns in the developing and adult murine brain.
  • Here we provide a detailed analysis of Prox1 mRNA and protein expression during prenatal and postnatal murine brain development.
  • Prenatally, Prox1 is expressed in the subventricular zone or in early differentiating regions of the brain.
  • At an early postnatal stage, Prox1 expression is mainly detected in several nuclei of the thalamus, the cerebellum, and the hippocampus.
  • These complex patterns of expression suggest that Prox1 activity is differentially required during brain development and adulthood.
  • [MeSH-major] Brain / embryology. Brain / growth & development. Gene Expression Regulation, Developmental. Homeodomain Proteins / metabolism. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117441.001).
  • [ISSN] 1058-8388
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-021765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Galactosides; 0 / Homeodomain Proteins; 0 / Indoles; 0 / Tumor Suppressor Proteins; 0 / prospero-related homeobox 1 protein; V595OG374W / 5-bromo-4-chloro-3-indolyl beta-galactoside
  •  go-up   go-down


Advertisement
4. Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL: Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol; 2006 Mar;1(3):205-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?
  • BACKGROUND: To determine whether the distribution, staging features, or tumor histology of non-small cell lung cancer (NSCLC) distinguishes neurologically symptomatic from asymptomatic patients initially diagnosed with lung cancer, and to determine whether these factors may predict the presence of brain metastasis.
  • METHODS: We performed a retrospective review of 809 patients with NSCLC and brain metastases who were treated in our institution between January 1996 and March 2003.
  • Patients who had brain metastasis on initial staging were included.
  • Thoracic computed tomographic scans were reviewed for lung tumor features and staging.
  • Neurological computed tomographic or magnetic resonance image scans were assessed for distribution of brain metastases.
  • Medical records were reviewed for comprehensive staging, tumor histology, and neurological symptoms.
  • Fisher's exact test was used to determine any differences among tumor histology, staging, and imaging features among patients with or without neurological symptoms.
  • RESULTS: Of the 809 patients, 181 had brain metastasis at initial staging.
  • Patients with adenocarcinoma and large-cell carcinoma had greater odds of brain metastases than patients with squamous cell carcinoma (p = 0.001).
  • No significant difference in tumor histology or T stage was found between groups, although group 2 was more likely to have a higher N stage.
  • Of the 181 patients with brain metastasis, 60 (33.1%) had N0 disease, 51 (28.2%) had T1 disease, and 23 (19.2%) had no other metastasis.
  • There was no correlation between number/distribution of brain metastases and tumor histology, although patients with disease in the cerebellum or temporal lobes had a greater likelihood of neurological symptoms (odds ratio 3.7).
  • CONCLUSION: There was no significant difference in tumor histology, staging, or distribution between symptomatic or asymptomatic patients with NSCLC with brain metastases.
  • The odds of brain metastases were greater in those with adenocarcinoma or large-cell carcinoma.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain / radiography. Carcinoma / diagnosis. Carcinoma / pathology. Carcinoma / secondary. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed


5. Guo N, Hei ZQ, Pang HY: [The comparative proteomic analysis of serum cytokine expression in acute lung injury patients in peri-operative stage of liver transplantation]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2009 Feb;21(2):74-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The comparative proteomic analysis of serum cytokine expression in acute lung injury patients in peri-operative stage of liver transplantation].
  • OBJECTIVE: To investigate the characteristics of serum cytokine expression in acute lung injury (ALI) patients in peri-operative stage of liver transplantation with the aim of setting the basis for screening the early markers and treatment targets of ALI.
  • METHODS: Four male patients with ALI occurring in peri-operative stage of liver transplantation for hepatitis B liver cirrhosis, with no lung, renal, or brain abnormality, without difference in clinical findings (urine volume, blood loss, ascites, amount of blood transfusion, operation time, anhepatic time, the use of vaso-active drugs, diuretics and condition of circulation) were included for study.
  • RESULTS: Compared with healthy people, in the patients with ALI in peri-operative stage of liver transplantation, upregulation of some cytokines appeared as early as after anesthesia, including interleukins (IL-3, IL-6, IL-12 p40, IL-12 p70), monocyte chemoattractant protein-2 (MCP-2), macrophage-colony stimulating factor (M-CSF), monokine induced by interferon-gamma (MIG), macro-phage inflammatory protein-1 alpha (MIP-1 alpha), soluble tumor necrosis factor receptor I (sTNFR I), especially sTNFR II which showed even stronger expression, while normal T cells expression and secretory factor (RANTES) and platelet-derived growth factor-BB (PDGF-BB) showed downregulation in expression.
  • [MeSH-minor] Adult. Chemokine CCL8 / blood. Humans. Interleukins / blood. Intraoperative Period. Macrophage Colony-Stimulating Factor / blood. Male. Middle Aged

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220953.001).
  • [ISSN] 1003-0603
  • [Journal-full-title] Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
  • [ISO-abbreviation] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chemokine CCL8; 0 / Cytokines; 0 / Interleukins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


6. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH: Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol; 2010 Nov;21(11):2169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival differences among women with de novo stage IV and relapsed breast cancer.
  • BACKGROUND: The objective of this retrospective study was to determine whether differences in survival exist between women with de novo stage IV and relapsed breast cancer.
  • PATIENTS AND METHODS: Three thousand five hundred and twenty-four women with de novo stage IV or relapsed breast cancer diagnosed from 1992 to 2007 were identified.
  • Cox proportional hazards model was fitted to determine the association between metastatic disease (relapsed versus de novo) and OS after controlling for other patient/tumor characteristics.
  • RESULTS: Six hundred and forty-three (18.2%) women had de novo stage IV disease and 2881 (81.8%) had relapsed disease.
  • Median OS among patients with de novo stage IV and relapsed disease was 39.2 and 27.2 months, respectively (P < 0.0001).
  • When the multivariable model was stratified by DFI, women with relapsed disease with DFI <6 months, ≥6 months to <2 years, or ≥2 to <5 years each had a significantly higher risk of death compared with women with de novo stage IV disease.
  • CONCLUSIONS: This large cohort study provides further insight into the natural history of relapsed and de novo stage IV breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):92-8 [19933921.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):197-207 [11885995.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):44-52 [14692023.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3302-8 [15310773.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3861-5 [476622.001]
  • [Cites] Cancer Res. 1989 Apr 15;49(8):1996-2001 [2702641.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1370-1 [1922240.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Apr;13(2):415-34 [10363138.001]
  • [Cites] Ann Surg. 2008 May;247(5):732-8 [18438108.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1696-702 [18357493.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4891-8 [18725649.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2012-9 [18641006.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1771-85 [19608616.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • (PMID = 20427349.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1K07 CA 109064
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2962259
  •  go-up   go-down


7. Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, Love C, Wenck S, Daggy J: Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer; 2005 Aug 1;104(3):570-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
  • BACKGROUND: The purpose of the current study was to determine the sensitivity and specificity of initial F-18 fluorodeoxy-D-glucose-positron emission tomography (FDG-PET) scanning for detection of occult lymph node and distant metastases in patients with early-stage cutaneous melanoma.
  • RESULTS: There were 144 assessable patients with a mean tumor depth of 2.8 mm.
  • Excluding patients with brain metastases, FDG-PET scan sensitivity for detection of occult Stage IV disease in patients was 0.04 (95% CI, 0.001-0.20) and specificity was 0.86 (95% CI, 0.79-0.92).
  • CONCLUSIONS: FDG-PET scanning did not impact the care of patients with early-stage melanoma already staged by standard techniques.
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15977211.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 74389-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


8. Nakazaki K, Titoku S, Ota S, Sato M, Kobanawa S, Tutida K, Tanaka Y, Goto K, Ota T: [Lacunar infarction in brain tumor patients: chronic stage complication after radiation therapy]. No Shinkei Geka; 2007 Oct;35(10):1019-23
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lacunar infarction in brain tumor patients: chronic stage complication after radiation therapy].
  • The tumor completely disappeared and he was able to return to work.
  • The patient had received radiation therapy for a suprasellar tumor when she was 11 years old.
  • The tumor considerably decreased in size and the patient conducted normal social life thereafter.
  • [MeSH-major] Brain Infarction / etiology. Brain Neoplasms / radiotherapy. Germinoma / radiotherapy. Hemangioma, Cavernous, Central Nervous System / radiotherapy. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Age Factors. Female. Humans. Magnetic Resonance Imaging. Male. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17969339.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Kim YB, Lee IJ, Kim SY, Kim JW, Yoon HI, Kim SW, Kim S, Kim YT, Suh CO, Kim GE: Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1323-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor heterogeneity of FIGO stage III carcinoma of the uterine cervix.
  • PURPOSE: The purpose of this study was to analyze tumor heterogeneity based on tumor extent and suggest reappraisal of the system of the International Federation of Gynecology and Obstetrics (FIGO) for Stage III carcinoma of the uterine cervix from a radiotherapeutic viewpoint.
  • METHODS AND MATERIALS: Between 1986 and 2004, 407 patients with FIGO Stage III (FIGO Stage IIIa in 19 and IIIb in 388) were treated with external beam radiotherapy (RT) and high-dose rate brachytherapy.
  • All patients were reviewed with respect to tumor extent.
  • RESULTS: The complete response rate was 79.6%, and the 5-year overall survival rates for Stage IIIa and Stage IIIb carcinoma of the cervix were 82.1% and 54.8%, respectively.
  • To determine which parameters of tumor extent had an influence on prognosis for Stage IIIb patients, pelvic wall (PW) extension and hydronephrosis (HD) retained significance on multivariate analysis.
  • Stage IIIb patients were divided into three subgroups according to PW extension and HD: low risk (unilateral PW extension without HD), intermediate risk (HD without PW extension or bilateral PW extension without HD), and high risk (unilateral or bilateral PW extension with HD).
  • CONCLUSIONS: FIGO Stage III carcinoma of the cervix covers considerably heterogeneous subgroups according to tumor extent.
  • Before initiation of treatment, we suggest that physicians determine a tailored treatment policy based on tumor heterogeneity for each Stage III patient.
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Brachytherapy / methods. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiotherapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Chi-Square Distribution. Female. Humans. Middle Aged. Survival Rate. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1605-6; author reply 1606-7 [20637983.001]
  • (PMID = 19467800.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Sultan I, Qaddoumi I, Rodríguez-Galindo C, Nassan AA, Ghandour K, Al-Hussaini M: Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors. Pediatr Blood Cancer; 2010 Jan;54(1):35-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.
  • Univariate and multivariate analyses showed that age at diagnosis (2-18 years), localized stage of tumors, and use of radiotherapy were significantly associated with improved survival.
  • Adults had a better outcome than young children (<2 years old) but a poorer outcome than older children (2-18 years old); tumor stage, but not radiotherapy use, affected outcome in adults.
  • CONCLUSION: Our population-based study indicates that age at diagnosis, tumor stage, and use of radiotherapy favorably impact survival rates of patients with MRTs.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radiotherapy. Kidney Neoplasms / pathology. Kidney Neoplasms / radiotherapy. Rhabdoid Tumor / pathology. Rhabdoid Tumor / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome. Young Adult


11. Pace A, Di Lorenzo C, Guariglia L, Jandolo B, Carapella CM, Pompili A: End of life issues in brain tumor patients. J Neurooncol; 2009 Jan;91(1):39-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] End of life issues in brain tumor patients.
  • Despite aggressive antitumor treatment, the prognosis of brain tumor (BT) patients remains poor.
  • In the last stage of disease, BT patients present severe symptoms due to the growing tumor or to treatment side-effects, which require adequate palliative management and supportive therapy.
  • This study explores symptoms experienced by BT patients in the last weeks of disease and EoL issues observed in a population of brain tumor patients followed at home until death by a neuro-oncological home care palliative unit set up in our Institution in 2000.
  • From October 2000 to December 2005, 324 patients affected by brain tumor and discharged from our Institution were enrolled in a comprehensive program of neuro-oncological home care supported by the Regional Health System.
  • Palliative management of brain tumor patients requires a multidisciplinary approach performed by a well trained neuro-oncology team.
  • Development of home care models of assistance may represent an alternative to in-hospital care for the management of patients dying of brain tumor and may improve the quality of end-of-life care.
  • [MeSH-major] Attitude to Death. Brain Neoplasms / epidemiology. Brain Neoplasms / psychology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Bereavement. Decision Making. Female. Humans. Male. Middle Aged. Palliative Care / psychology. Quality of Life. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2009 Jan;91(1):45. Lorenzo, Cherubino Di [corrected to Di Lorenzo, Cherubino]
  • (PMID = 18704267.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young LT, Yatham LN: Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol; 2009 May;12(4):447-58
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.
  • Changes in brain-derived neurotrophic factor (BDNF) levels and cytokines are potential candidates.
  • BDNF was decreased only in those patients in the late stage of bipolar disorder.
  • When levels were compared between patients at early and late stages of illness, there was a significant decrease in BDNF and IL-6 in the later stage of BD compared to the early stage.
  • Inversely, TNF-alpha showed a significant increase at the later stage.
  • Failure of inflammatory defences in the late stage of the disorder may account for reduction in BDNF and continued elevations in cytokines; thus these may have the potential to serve as markers of illness progression in BD.

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18771602.001).
  • [ISSN] 1469-5111
  • [Journal-full-title] The international journal of neuropsychopharmacology
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Brain-Derived Neurotrophic Factor; 0 / Cytokines; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


13. Pitskhelauri DI, Konovalov AN, Kornienko VN, Serova NK, Arutiunov NV, Kopachev DN: Intraoperative direct third ventriculostomy and aqueductal stenting in deep-seated midline brain tumor surgery. Neurosurgery; 2009 Feb;64(2):256-66; discussion 266-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative direct third ventriculostomy and aqueductal stenting in deep-seated midline brain tumor surgery.
  • OBJECTIVE: Surgical resection of deep-seated midline brain tumors does not always resolve obstruction of cerebrospinal fluid pathways, and an additional operation--ventricular shunting--is required.
  • To prevent postoperative obstructive hydrocephalus, we combine tumor removal and internal ventricular shunting in 1 stage.
  • METHODS: Between 2000 and 2006, 82 patients with deep-seated midline brain tumors (tumors of the third ventricle, pineal region, thalamus, upper brainstem, and superior half of the fourth ventricle) underwent 84 tumor resections with intraoperative internal ventricular shunting.
  • RESULTS: As most of the tumors had an infiltrative growth pattern, gross total tumor removal was achieved in only 31% of patients in this series.
  • CONCLUSION: Intraoperative direct third ventriculostomy and aqueductal stenting under direct visual control were found to be reliable methods of hydrocephalus management in patients with deep-seated midline brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Cerebral Ventricles / surgery. Cerebrospinal Fluid Shunts / instrumentation. Cerebrospinal Fluid Shunts / methods. Ventriculostomy / instrumentation. Ventriculostomy / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Intraoperative Care / instrumentation. Intraoperative Care / methods. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190455.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Padovani L, André N, Carrie C, Muracciole X: [Childhood and adult medulloblastoma: what difference?]. Cancer Radiother; 2009 Oct;13(6-7):530-5
Genetic Alliance. consumer health - Medulloblastoma, childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood and adult medulloblastoma: what difference?].
  • Medulloblastoma is the most frequent childhood brain tumor (30%) but account only for less than 1% of adult brain tumor.
  • The overall survival increased significantly during the last two decades with 80% of long survivors at five years whatever the stage.
  • Due to the rarety in adult population, no prospective studies and few data about late effects are available.
  • Adult medulloblastoma is a therapeutic challenge and their therapeutic strategies are similar to pediatric protocols.
  • In order to improve the understanding of adult disease and to homogenize the treatment, National Cancer Institute (INCa) stimulated the creation of web conference to discuss each case prospectively and to propose a protocol of treatment.
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / epidemiology. Child. Cognition Disorders / epidemiology. Cognition Disorders / etiology. Combined Modality Therapy. France / epidemiology. Humans. Incidence. Molecular Biology / methods. Radiotherapy / adverse effects. Radiotherapy / methods. Surgical Procedures, Operative

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713143.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol; 2007 Feb;37(2):108-13
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of stage III and IV adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs.
  • We report surgical outcome of stage III and IV ACCs.
  • METHODS: ACCs from seven patients at clinical stage II (n = 1), III (n = 4), or IV (n = 2) were resected.
  • RESULTS: The pathological stage was stage III in five patients and stage IV in two patients.
  • The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11-58).
  • The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively.
  • Loco-regional, intra-abdominal lymph node, peritoneum, bone, brain recurrences were also seen in one patient each.
  • CONCLUSIONS: Resection for stage III, IV ACCs affords the possibility of negative margins, acceptable peri-operative morbidity and mortality, and prolongs survival in selected patients.
  • [MeSH-minor] Adult. Aged. Female. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277000.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


16. Sinescu I, Manu MA, Hârza M, Serbãnescu B, Stefan B, Cerempei V, Tacu D, Kerezsy E, Bucşa C, Domnişor L, Daia D, Constantinescu I: Renal transplantation--substitution therapy in advanced stage uremia. J Med Life; 2008 Apr-Jun;1(2):108-17
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal transplantation--substitution therapy in advanced stage uremia.
  • Advanced stage chronic renal failure (CRF) uremia represents one of the most severe metabolic "catastrophes" of the organism.
  • During the last 10 years, renal transplantations with kidneys from brain dead donors (multiorgan harvesting) to an adult (1997), a child (1999), a diabetic recipient (1998) and an unephric child due to bilateral Wilms' tumor (2005) were performed at "Fundeni" Renal Transplantation Center as a national première.
  • Among these, 152 transplants were performed using kidneys harvested from brain dead donors.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20108457.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 20
  •  go-up   go-down


17. Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, Soyka JD, Veit-Haibach P, Seifert B, Kalff V: Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging; 2008 Oct;35(10):1786-95
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B.
  • PURPOSE: This study aims to compare the use of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B in chemotherapy response assessment of stage IV melanoma patients.
  • METHODS: In 25 patients with stage IV melanoma, FDG-PET/CT and S-100B after 2-3 months (three cycles) of chemotherapy was compared with baseline PET/CT and baseline S-100B.
  • In patients with clinical suspicion for brain metastases, MRI or CCT was performed.
  • Eleven patients developed brain metastases during treatment, first detected by PET/CT in two and by MRI or CCT in nine of 11 patients.
  • Appearance of brain metastases was associated with a poor survival.
  • PET/CT responders have better early survival, but this is shortlived due to late therapy failure--often with brain recurrence.
  • Additional brain MRI for therapy response assessment in such high-risk patients is mandatory to detect brain metastases missed by PET/CT.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain / diagnostic imaging. Brain / pathology. Fluorodeoxyglucose F18. Magnetic Resonance Imaging / methods. Melanoma. Nerve Growth Factors / blood. Positron-Emission Tomography / methods. S100 Proteins / blood. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Humans. Middle Aged. Outcome Assessment (Health Care) / methods. Prognosis. Radiopharmaceuticals. Reproducibility of Results. Retrospective Studies. S100 Calcium Binding Protein beta Subunit. Sensitivity and Specificity. Subtraction Technique. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:36S-44S [17204719.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):748-59 [14662431.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1293-300 [15051777.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23 (21):4577-80 [15837974.001]
  • [Cites] Oncology. 2005;68(4-6):341-9 [16020961.001]
  • [Cites] Onkologie. 2002 Feb;25(1):74-6 [11928697.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23 (33):8362-70 [16293866.001]
  • [Cites] Semin Nucl Med. 2005 Jul;35(3):186-96 [16098292.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Neuroradiology. 1981;22(3):123-7 [7312160.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10 ):1626-32 [17873129.001]
  • [Cites] Dermatology. 1997;194(3):208-12 [9187834.001]
  • [Cites] Dermatology. 2007;215(3):192-201 [17823514.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Nucl Med. 2006 May;47(5):885-95 [16644760.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Pathol Oncol Res. 1999;5(3):218-22 [10491021.001]
  • [Cites] Br J Dermatol. 1999 Jun;140(6):1065-71 [10354072.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1329-37 [17623835.001]
  • [Cites] N Engl J Med. 2006 Feb 2;354(5):496-507 [16452561.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):45-9 [12569284.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1178-87 [16505438.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Apr;21(4):611-4; discussion 614-5 [11932155.001]
  • [Cites] Eur J Cancer. 1978 Apr;14(4):327-30 [648555.001]
  • [Cites] Eur J Cancer. 1995 Oct;31A(11):1898-902 [8541129.001]
  • [Cites] Radiology. 2003 Jan;226(1):181-7 [12511688.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1144-50 [16000283.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1366-75 [17390135.001]
  • [Cites] J Nucl Med. 2007 Oct;48(10 ):1592-8 [17873138.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):607-10 [15762365.001]
  • [Cites] Melanoma Res. 1999 Feb;9(1):51-8 [10338334.001]
  • [Cites] Radiology. 2007 Aug;244(2):566-74 [17641374.001]
  • [Cites] Clin Nucl Med. 2006 Nov;31(11):707-8 [17053391.001]
  • [Cites] Br J Dermatol. 1997 Sep;137(3):381-5 [9349333.001]
  • (PMID = 18458901.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Nerve Growth Factors; 0 / Radiopharmaceuticals; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Kouyialis AT, Boviatsis EI, Karampelas IK, Korfias S, Korkolopoulou P, Sakas DE: Primitive supratentorial neuroectodermal tumor in an adult. J Clin Neurosci; 2005 May;12(4):492-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive supratentorial neuroectodermal tumor in an adult.
  • Total removal of the tumour was achieved in a two-stage procedure.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neuroectodermal Tumors, Primitive / pathology. Supratentorial Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Neuroglia / pathology. Review Literature as Topic

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925794.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


19. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H: Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology; 2007 Mar;242(3):882-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases.
  • PURPOSE: To retrospectively assess possible clinical predictors of metastatic disease to the brain in patients with non-small cell lung carcinoma (NSCLC).
  • Hierarchical logistic regression was used to determine the predicted probability of metastatic disease to the brain as a function of patient age and sex and of size, cell type, peripheral versus central location, and lymph node stage of the primary NSCLC.
  • RESULTS: Ninety-five (36%) patients had evidence of metastatic disease to the brain.
  • Cell types included adenocarcinoma (136 [52%] patients), undifferentiated (68 [26%] patients), and squamous (47 [18%] patients), for which metastatic disease to the brain occurred in 43%, 41%, and 13% (P = .003) of patients, respectively.
  • The predicted probability of metastatic disease to the brain correlated positively with size of the primary tumor (P < .001), cell type (adenocarcinoma and undifferentiated vs squamous, P = .001), and lymph node stage (P < .017) but did not correlate with age, sex, or primary tumor location.
  • For primary adenocarcinoma without lymph node spread, the predicted probabilities of metastatic disease to the brain from 2- and 6-cm primary tumors were .14 (95% confidence interval: .06, .27) and .72 (95% confidence interval: .48, .88), respectively (P < .02).
  • CONCLUSION: The probability of metastatic disease to the brain from primary NSCLC is correlated with size of the primary tumor, cell type, and intrathoracic lymph node stage.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / epidemiology. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / epidemiology. Risk Assessment / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. New York / epidemiology. Prevalence. Risk Factors. Sex Distribution

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229875.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Virgintino D, Errede M, Girolamo F, Capobianco C, Robertson D, Vimercati A, Serio G, Di Benedetto A, Yonekawa Y, Frei K, Roncali L: Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development. J Neuropathol Exp Neurol; 2008 Jan;67(1):50-61
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development.
  • During brain development and blood-brain barrier (BBB) differentiation the expression of P-glycoprotein (P-gp) may complement the protective function of the placental barrier against xenobiotic substances.
  • The protocol was then tested on adult human brains as a BBB-P-gp tissue-specific control and for double labeling with anti-P-gp and the astroglia marker glial fibrillary acidic protein (GFAP).
  • At the earliest examined stage, 12 weeks of gestation (wg), P-gp was detectable as diffuse cytoplasmic labeling of the endothelial cells lining the primary cortex microvessels.
  • [MeSH-major] Blood-Brain Barrier / embryology. Blood-Brain Barrier / metabolism. Brain / embryology. Brain / metabolism. Human Development / physiology. P-Glycoprotein / physiology
  • [MeSH-minor] Adult. Age Factors. Carcinoma / metabolism. Caveolins / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Female. Fetus. Fibrosarcoma / metabolism. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Vimentin / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091560.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolins; 0 / Glial Fibrillary Acidic Protein; 0 / P-Glycoprotein; 0 / Vimentin
  •  go-up   go-down


21. Jiang F, Xu L, Yuan FL, Huang JF, Lu XX, Zhang XY: [Lung auto-transplantation technique in the treatment for stage III central lung cancer]. Zhonghua Yi Xue Za Zhi; 2010 May 18;90(19):1329-32
MedlinePlus Health Information. consumer health - Lung Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung auto-transplantation technique in the treatment for stage III central lung cancer].
  • OBJECTIVE: To assess the feasibility and benefit of lung auto-transplantation technique in surgical treatment for stage III central lung cancer.
  • Since the length of resected bronchus or pulmonary artery involved by tumor was too long to perform tension-free anastomosis, we transplanted the inferior pulmonary vein to the proximal stump of the superior pulmonary vein.
  • Until Jan 2008, six of the eight patients who underwent lung autotransplantations, had been free of tumor recurrence for 7-90 months with good quality of life.
  • Another patient died of brain metastases 31 months postoperatively.
  • CONCLUSION: Lung auto-transplantation is an alternative technique for pulmonary preservation for patient with stage III centrally placed lung cancer, whose cardio-pulmonary functions is too poor to undergo pneumonectomy.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646582.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


22. Kawai N, Okauchi M, Miyake K, Sasakawa Y, Yamamoto Y, Nishiyama Y, Tamiya T: [11C-methionine positron emission tomography in nontumorous brain lesions]. No Shinkei Geka; 2010 Nov;38(11):985-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C-methionine positron emission tomography in nontumorous brain lesions].
  • Positron emission tomography (PET) with L-[methyl-11C]methionine (MET) provides information on the metabolism of brain tumor.
  • MET uptake reflects amino acid active transport and protein synthesis and is proportional to the amount of viable tumor cells.
  • However, MET uptake can be increased as a result of increased density of inflammatory cells and disruption of the blood brain barrier (BBB) in nontumorous brain lesions.
  • From October 2005 through November 2009, 438 MET-PET studies were performed for various brain lesions at our institution.
  • Nine of 10 intracerebral hemorrhages and all 4 cerebral infarctions demonstrated mild to moderate MET uptake in or surrounding the lesions in the subacute or chronic stage after the ictus.
  • Moderately increased MET uptake was observed in all 3 patients with brain abscess.
  • We should keep in mind that high MET uptake is frequently observed in nontumorous brain lesions.
  • [MeSH-major] Brain Diseases / radionuclide imaging. Methionine / metabolism. Positron-Emission Tomography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain Abscess / radionuclide imaging. Carbon Radioisotopes. Cerebral Infarction / radionuclide imaging. Encephalocele / radionuclide imaging. Female. Glioma / radionuclide imaging. Humans. Male. Middle Aged. Nervous System Diseases / radionuclide imaging. Optic Nerve Diseases / radionuclide imaging. Orbital Diseases / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081810.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


23. Cetingöz R, Cetinayak HO, Sen RC, Demiral AN, Akkoçlu A, Osma E, Kargi A, Oztop I, Onen A, Kinay M, Dokuz Eylül Lung Cancer Study Group: Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach. J BUON; 2006 Jan-Mar;11(1):31-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.
  • PURPOSE: To evaluate the combined modality treatment results of patients with limited-stage small cell lung cancer (SCLC), who were treated and followed by the DELCSG.
  • PATIENTS AND METHODS: Sixty-three patients with limited-stage SCLC diagnosed between April 1991 and December 2002 were included.
  • A total dose of 5000 cGy with 180-200 cGy daily fractions was given to the primary tumor and mediastinum, excluding the spinal cord after 4500 cGy.
  • During follow-up, 27 (43%) patients developed brain metastasis; among them only 3 had received PCI.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / therapeutic use. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318949.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CAV protocol; VP-P protocol
  •  go-up   go-down


24. Chen Y, Zhang H, Xu A, Li N, Liu J, Liu C, Lv D, Wu S, Huang L, Yang S, He D, Xiao X: Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer; 2006 Oct;54(1):95-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer.
  • To identify potential biomarkers related with lung cancer metastasis, conditional media (CM) proteins collected from a primary non-small cell lung cancer (NSCLC) cell line NCI-H226 and its brain metastatic subline H226Br were analyzed by one-dimensional electrophoresis (1-D PAGE) and matrix-assisted laser desorption/time of flight mass spectrometry (MALDI-TOF-MS).
  • It was found that the levels of LDHB were specifically elevated in NSCLC sera compared with other groups and were progressively increased with the clinical stage.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / enzymology. L-Lactate Dehydrogenase / blood. Lung Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Electrophoresis, Polyacrylamide Gel. Enzyme-Linked Immunosorbent Assay. Female. Humans. Isoenzymes / blood. Male. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890323.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 1
  •  go-up   go-down


25. Marsh J, Mukherjee P, Seyfried TN: Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res; 2008 Dec 1;14(23):7751-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma.
  • PURPOSE: Malignant astrocytomas exhibit constitutive Akt phosphorylation due to reduced phosphatase and tensin homologue (PTEN) tumor suppressor expression or to increased growth factor receptor tyrosine kinase activation.
  • Although dietary restriction (DR) reduces glycolysis and manages early-stage astrocytoma growth, no prior studies have identified the mechanisms involved or determined if DR can also manage late-stage tumor growth.
  • EXPERIMENTAL DESIGN: The effects of a late-onset intermittent DR feeding paradigm were examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown orthotopically or subcutaneously.
  • RESULTS: In contrast to contralateral normal brain, CT-2A was PTEN/TSC2 protein deficient; exhibited constitutive Akt, mTOR, and BAD phosphorylation; and overexpressed insulin-like growth factor-I (IGF-I), IGF-I receptor, hypoxia-inducible transcription factor-1alpha (HIF-1alpha), type 1 glucose transporter protein (GLUT1), and pyruvate kinase.
  • DR initiated 10 to 14 days after tumor implantation (late onset) reduced CT-2A growth, delayed malignant progression, and significantly extended survival.
  • [MeSH-major] Astrocytoma / diet therapy. Brain Neoplasms / diet therapy. PTEN Phosphohydrolase / deficiency. Proto-Oncogene Proteins c-akt / metabolism. Tumor Suppressor Proteins / deficiency

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047102.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102135; United States / NINDS NIH HHS / NS / NS 055195
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 4JG2LF96VF / tuberous sclerosis complex 2 protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


26. Shah H, Anker CJ, Bogart J, Graziano S, Shah CM: Brain: the common site of relapse in patients with pancoast or superior sulcus tumors. J Thorac Oncol; 2006 Nov;1(9):1020-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain: the common site of relapse in patients with pancoast or superior sulcus tumors.
  • PURPOSE: We conducted a retrospective analysis to determine the occurrence of brain metastasis with superior sulcus tumors.
  • Twenty-nine out of 685 patients (4%) had a diagnosis of Pancoast or superior sulcus tumor.
  • Regarding stage at presentation: seven patients had stage IIB, two had stage IIIA, 16 had stage IIIB, and four had stage IV.
  • The total occurrence of brain metastasis is seven out of 29 patients (24%).
  • Two patients (stage IV) had brain metastasis at the time of presentation and five patients (stage IIB-III) developed brain metastasis at a median time of 10 months after the diagnosis.
  • Stage associated with brain metastasis after diagnosis is two patients for stage IIB, two for stage IIIA, and one for stage IIIB.
  • For the 25 patients with stage IIB to stage III disease, nine (36%) developed distant metastasis after definitive therapy.
  • Out of these nine patients, five (55%) developed brain metastasis.
  • Histology for seven patients with brain metastasis was four of seven with adenocarcinoma, two of seven with squamous cell carcinoma, and one of seven with NSCLC.
  • CONCLUSION: Brain metatasis may be relatively common at diagnosis.
  • The brain is the frequent site of failure for superior sulcus tumors.
  • We recommend careful surveillance for brain metastasis during and after the therapy.
  • We also recommend obtaining brain imaging prior to surgery in patients receiving induction therapy for the primary tumor.
  • [MeSH-major] Brain Neoplasms / epidemiology. Brain Neoplasms / secondary. Lung Neoplasms / pathology. Pancoast Syndrome / epidemiology. Pancoast Syndrome / secondary
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Incidence. Lung / anatomy & histology. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409988.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Chen LJ, Jia YX, Fan FF, Li XY: [Expression of FLI-1 and analysis of prognostic factors in primitive neuroectodermal tumor]. Zhonghua Zhong Liu Za Zhi; 2010 Dec;32(12):917-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of FLI-1 and analysis of prognostic factors in primitive neuroectodermal tumor].
  • Immmunohistochemistry (The En Vision method) was applied to detect the expression of FLI-1, CD99, Syn, NSE, S-100, NF, Vim in the tumor tissues.
  • Cox regression analysis showed that the impact of primary location and treatment modality were of statistical significance (P < 0.05), but the age, sex, stage or size of tumors did not (P > 0.05).
  • [MeSH-major] Brain Neoplasms. Neuroectodermal Tumors, Primitive. Neuroectodermal Tumors, Primitive, Peripheral. Pelvic Neoplasms. Proto-Oncogene Protein c-fli-1 / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Phosphopyruvate Hydratase / metabolism. Proportional Hazards Models. S100 Proteins / metabolism. Survival Rate. Synaptophysin / metabolism. Vimentin / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21223800.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / FLI1 protein, human; 0 / Proto-Oncogene Protein c-fli-1; 0 / S100 Proteins; 0 / Synaptophysin; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


28. Attardo A, Fabel K, Krebs J, Haubensak W, Huttner WB, Kempermann G: Tis21 expression marks not only populations of neurogenic precursor cells but also new postmitotic neurons in adult hippocampal neurogenesis. Cereb Cortex; 2010 Feb;20(2):304-14
Hazardous Substances Data Bank. BROMODEOXYURIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tis21 expression marks not only populations of neurogenic precursor cells but also new postmitotic neurons in adult hippocampal neurogenesis.
  • We here investigated if the expression pattern of Tis21 also correlates with the generation of new neurons in the adult hippocampus.
  • We used Tis21 knock-in mice expressing green fluorescent protein (GFP) and studied Tis21-GFP expression together with markers of adult hippocampal neurogenesis in newly generated cells.
  • We found that Tis21-GFP 1) was absent from the radial glia-like putative stem cells (type-1 cells), 2) first appeared in transient amplifying progenitor cells (type-2 and 3 cells), 3) did not colocalize with markers of early postmitotic maturation stage, 4) was expressed again in maturing neurons, and 5) finally decreased in mature granule cells.
  • Our data show that, in the course of adult neurogenesis, Tis21 is expressed in a phase additional to the one of the embryonic neurogenesis.
  • This additional phase of expression might be associated with a new and different function of Tis21 than during embryonic brain development, where no Tis21 is expressed in mature neurons.
  • Tis21 can thus serve as new marker for key stages of adult neurogenesis.
  • [MeSH-major] Hippocampus / growth & development. Hippocampus / metabolism. Immediate-Early Proteins / genetics. Neurogenesis / genetics. Neurons / metabolism. Stem Cells / metabolism. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Neurosci. 2008 Aug;11(8):888-93 [18587391.001]
  • [Cites] PLoS Biol. 2008 Oct 7;6(10):e246 [18842068.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1797-815 [10669755.001]
  • [Cites] Nature. 2002 Feb 28;415(6875):1030-4 [11875571.001]
  • [Cites] J Neurosci Res. 2002 Nov 1;70(3):327-34 [12391592.001]
  • [Cites] Development. 2003 Jan;130(2):391-9 [12466205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11866-72 [12923297.001]
  • [Cites] J Comp Neurol. 2003 Dec 1;467(1):1-10 [14574675.001]
  • [Cites] Eur J Neurosci. 2003 Nov;18(10):2707-12 [14656319.001]
  • [Cites] Mol Cell Neurosci. 2003 Nov;24(3):603-13 [14664811.001]
  • [Cites] Eur J Neurosci. 2004 Jan;19(2):234-46 [14725617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3196-201 [14963232.001]
  • [Cites] J Neurosci. 2004 Mar 31;24(13):3355-69 [15056715.001]
  • [Cites] Nature. 2004 May 13;429(6988):184-7 [15107864.001]
  • [Cites] Neuron. 2004 May 27;42(4):535-52 [15157417.001]
  • [Cites] Trends Neurosci. 2004 Aug;27(8):447-52 [15271491.001]
  • [Cites] Neurosci Lett. 2004 Oct 7;369(1):24-7 [15380301.001]
  • [Cites] J Comp Neurol. 1975 Jan 15;159(2):149-75 [1112911.001]
  • [Cites] J Comp Neurol. 1987 Oct 22;264(4):449-79 [3680638.001]
  • [Cites] Exp Neurol. 1990 Jan;107(1):23-35 [2295317.001]
  • [Cites] J Comp Neurol. 1990 Nov 15;301(3):365-81 [2262596.001]
  • [Cites] Cell Calcium. 1990 Oct;11(9):599-602 [2285928.001]
  • [Cites] Development. 1992 Sep;116(1):201-11 [1483388.001]
  • [Cites] Neuron. 1994 Apr;12(4):895-908 [8161459.001]
  • [Cites] Mech Dev. 1994 Aug;47(2):127-37 [7811636.001]
  • [Cites] Nat Genet. 1996 Dec;14(4):482-6 [8944033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4639-44 [10200315.001]
  • [Cites] PLoS One. 2008;3(6):e2388 [18545663.001]
  • [Cites] Neuroscience. 2008 Jun 23;154(2):521-9 [18502050.001]
  • [Cites] Eur J Neurosci. 2005 Jan;21(1):1-14 [15654838.001]
  • [Cites] J Neurosci. 2005 Jul 13;25(28):6533-8 [16014714.001]
  • [Cites] Annu Rev Neurosci. 2005;28:223-50 [16022595.001]
  • [Cites] Neuron. 2005 Sep 15;47(6):803-15 [16157276.001]
  • [Cites] J Neurosci. 2005 Nov 9;25(45):10366-8 [16280573.001]
  • [Cites] Mol Cell Neurosci. 2006 Aug;32(4):344-55 [16828306.001]
  • [Cites] Glia. 2006 Dec;54(8):805-14 [16958090.001]
  • [Cites] BMC Neurosci. 2006;7:77 [17105671.001]
  • [Cites] Nature. 2007 Jan 11;445(7124):168-76 [17151600.001]
  • [Cites] Nat Neurosci. 2007 Mar;10(3):355-62 [17277773.001]
  • [Cites] Neuron. 2007 May 24;54(4):559-66 [17521569.001]
  • [Cites] Eur J Neurosci. 2007 May;25(9):2591-603 [17466019.001]
  • [Cites] Cell Tissue Res. 2007 Sep;329(3):409-20 [17541643.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12764-74 [18032648.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20558-63 [18077357.001]
  • [Cites] J Neurosci. 2008 Apr 2;28(14):3707-17 [18385329.001]
  • [Cites] Neural Dev. 2008;3:13 [18507846.001]
  • (PMID = 19482889.001).
  • [ISSN] 1460-2199
  • [Journal-full-title] Cerebral cortex (New York, N.Y. : 1991)
  • [ISO-abbreviation] Cereb. Cortex
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Btg2 protein, mouse; 0 / Immediate-Early Proteins; 0 / Microtubule-Associated Proteins; 0 / Neuropeptides; 0 / Recombinant Fusion Proteins; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, mouse; 0 / Tumor Suppressor Proteins; 0 / doublecortin protein; 147336-22-9 / Green Fluorescent Proteins; G34N38R2N1 / Bromodeoxyuridine
  • [Other-IDs] NLM/ PMC2803732
  •  go-up   go-down


29. Nasonkin I, Mahairaki V, Xu L, Hatfield G, Cummings BJ, Eberhart C, Ryugo DK, Maric D, Bar E, Koliatsos VE: Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells; 2009 Oct;27(10):2414-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.
  • Here we studied the ability of HESC-derived NP grafts optimized for cell number and differentiation stage prior to transplantation, to survive and stably differentiate and integrate in the basal forebrain (neostriatum) of young adult nude rats over long periods of time (6 months).
  • Our findings demonstrate the long-term ability of noggin-derived human NPs to structurally integrate tumor-free into the mature mammalian forebrain, while maintaining some cell fate plasticity that is strongly influenced by particular central nervous system (CNS) niches.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cereb Cortex. 2000 Aug;10(8):729-47 [10920046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16707-12 [18922775.001]
  • [Cites] Neuron. 2000 Dec;28(3):713-26 [11163261.001]
  • [Cites] Development. 2001 Oct;128(19):3759-71 [11585802.001]
  • [Cites] Nat Biotechnol. 2001 Dec;19(12):1129-33 [11731781.001]
  • [Cites] Nat Rev Neurosci. 2002 Apr;3(4):271-80 [11967557.001]
  • [Cites] Neuron. 2002 Aug 29;35(5):865-75 [12372282.001]
  • [Cites] J Neurosci. 2003 Jan 1;23(1):167-74 [12514213.001]
  • [Cites] BMC Neurosci. 2001;2:9 [11399205.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):911-21 [12796477.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):417-24 [12849120.001]
  • [Cites] Stem Cells. 2003;21(5):521-6 [12968106.001]
  • [Cites] BMC Neurosci. 2003 Oct 22;4:27 [14572319.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12543-8 [15310843.001]
  • [Cites] Neuroscience. 1986 Oct;19(2):465-93 [3022187.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):556-8 [1699131.001]
  • [Cites] Prog Brain Res. 1990;82:391-9 [1705355.001]
  • [Cites] Brain Res. 1994 Dec 30;668(1-2):211-9 [7704606.001]
  • [Cites] Dev Biol. 1995 Apr;168(2):342-57 [7729574.001]
  • [Cites] Exp Neurol. 1996 Jan;137(1):15-25 [8566206.001]
  • [Cites] Mech Dev. 1996 Sep;59(1):89-102 [8892235.001]
  • [Cites] J Neurosci. 1997 Aug 1;17(15):5858-67 [9221783.001]
  • [Cites] Nature. 1997 Dec 18-25;390(6661):680-3 [9414159.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1438-52 [9585504.001]
  • [Cites] Stem Cells. 2004;22(6):925-40 [15536184.001]
  • [Cites] Nat Biotechnol. 2005 Feb;23(2):215-21 [15685164.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2475-85 [15743839.001]
  • [Cites] Nat Biotechnol. 2005 May;23(5):601-6 [15852001.001]
  • [Cites] J Neurosci. 2005 May 11;25(19):4694-705 [15888645.001]
  • [Cites] Stem Cells Dev. 2005 Jun;14(3):266-9 [15969621.001]
  • [Cites] J Neurosci. 2005 Sep 21;25(38):8714-24 [16177041.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14069-74 [16172374.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1234-41 [16002783.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1242-50 [16210408.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):41-53 [16387638.001]
  • [Cites] Neuron. 2006 Jan 5;49(1):55-66 [16387639.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1319-24 [16432194.001]
  • [Cites] Stem Cells. 2006 Jan;24(1):125-38 [16100006.001]
  • [Cites] Stem Cells Dev. 2006 Apr;15(2):254-9 [16646671.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1583-93 [16543488.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1433-40 [16556709.001]
  • [Cites] Exp Neurol. 2006 Oct;201(2):525-9 [16806174.001]
  • [Cites] Curr Opin Genet Dev. 2006 Oct;16(5):455-62 [16920351.001]
  • [Cites] Transplantation. 2006 Oct 15;82(7):865-75 [17038899.001]
  • [Cites] Eur J Neurosci. 2006 Oct;24(7):1885-96 [17067292.001]
  • [Cites] Dev Cell. 2006 Dec;11(6):831-44 [17141158.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):411-8 [17038668.001]
  • [Cites] J Neurosci. 2007 Feb 21;27(8):1836-52 [17314281.001]
  • [Cites] Neurobiol Aging. 2007 Aug;28(8):1148-62 [16859812.001]
  • [Cites] Glia. 2007 Aug 15;55(11):1156-68 [17597119.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):1931-9 [17478583.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e39 [17298165.001]
  • [Cites] J Neurosci. 2007 Nov 21;27(47):12787-96 [18032650.001]
  • [Cites] Cell. 2007 Nov 30;131(5):861-72 [18035408.001]
  • [Cites] Expert Opin Biol Ther. 2008 Feb;8(2):137-41 [18194070.001]
  • [Cites] Curr Protoc Neurosci. 2005 Nov;Chapter 3:Unit 3.18 [18428621.001]
  • [Cites] EMBO J. 2000 Oct 16;19(20):5460-72 [11032813.001]
  • (PMID = 19609935.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / DC000232; United States / NINDS NIH HHS / NS / R01 NS045140; United States / NINDS NIH HHS / NS / NS45140-03; United States / NEI NIH HHS / EY / P30 EY001765; United States / NIDCD NIH HHS / DC / DC000232-23; United States / NIDCD NIH HHS / DC / R01 DC000232-23; United States / NIDCD NIH HHS / DC / DC005211-089002; United States / NIDCD NIH HHS / DC / R01 DC000232; United States / NIDCD NIH HHS / DC / P30 DC005211; United States / NINDS NIH HHS / NS / R01 NS045140-03; United States / NEI NIH HHS / EY / EY01765; United States / NINDS NIH HHS / NS / NS045140-03; United States / NIDCD NIH HHS / DC / P30 DC005211-089002
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Phosphoproteins; 148294-77-3 / noggin protein
  • [Other-IDs] NLM/ NIHMS193803; NLM/ PMC2906132
  •  go-up   go-down


30. German-Fattal M, Lecerf F, Sabbagh F, Maurois P, Durlach J, Bac P: Neuroprotective gene profile in the brain of magnesium-deficient mice. Biomed Pharmacother; 2008 Apr-May;62(4):264-72
Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroprotective gene profile in the brain of magnesium-deficient mice.
  • In the current study, we explore endothelial cell activation, inflammation and cell death induced in the brain of adult mice by Mg-deficient diet.
  • METHODS AND RESULTS: Neither TNFalpha, substance P, sTNFRI, sTNFRII proteins (ELISA), nor TNFalpha, adherence molecules and prolactin mRNAs, nor NK1R (immunohistochemistry on brain sections) were up-regulated.
  • Using cDNA assay, we showed a neuroprotective, anti-apoptotic and neurotrophic gene expression profile in the brain at early stage of hypomagnesemia.
  • As a model for neuronal injury, mild sound stimulation of Mg-deficient mice without convulsive seizures triggers neither the release of substance P, nor the development of an inflammatory process or cell death in the brain.
  • CONCLUSION: Our results suggest that Mg-deficiency in mice favours the development of a neuroprotective environment in the brain.
  • [MeSH-major] Brain / metabolism. Gene Expression Profiling. Magnesium Deficiency / metabolism
  • [MeSH-minor] Animals. Apoptosis. Female. Immunohistochemistry. Inflammation / etiology. Intercellular Adhesion Molecule-1 / analysis. Intercellular Adhesion Molecule-1 / genetics. Interleukin-2 / analysis. Magnesium / metabolism. Mice. Prolactin / genetics. Receptors, Cannabinoid / genetics. Receptors, Granulocyte Colony-Stimulating Factor / genetics. Receptors, Tumor Necrosis Factor / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18400454.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Receptors, Cannabinoid; 0 / Receptors, Granulocyte Colony-Stimulating Factor; 0 / Receptors, Tumor Necrosis Factor; 126547-89-5 / Intercellular Adhesion Molecule-1; 9002-62-4 / Prolactin; I38ZP9992A / Magnesium
  •  go-up   go-down


31. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E: Factors affecting the prognosis of breast cancer patients with brain metastases. Breast; 2008 Oct;17(5):451-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the prognosis of breast cancer patients with brain metastases.
  • The aim of this retrospective analysis was to investigate the factors affecting the prognosis of brain metastases in breast cancer patients to identify subgroups which might benefit from prophylactic treatments in future.
  • Seventy-three early and 13 advanced stage patients with known Erb-2 status were included.
  • In 14% of the early stage patients, the first recurrence site was isolated brain metastasis.
  • None of the anthracycline resistant patients had brain metastases as their first recurrence site.
  • The median interval between diagnosis and brain metastasis was 41.5 months (95% CI, 35.79-47.20) in early stage patients.
  • The median interval between the first extracerebral metastases to the brain metastases was 15.5 months (95% CI, 12.24-18.76) in all patients.
  • High histologic and nuclear grade, large tumor, anthracycline resistance were the factors which significantly affected the early appearance of brain metastases but only advanced age (> or =55 years, P=.035) correlated with isolated brain metastasis.
  • Progression with isolated brain metastases was significantly higher in responsive ErbB-2 positive population (P=.036) and none of other pathological factors was associated with isolated brain metastasis in advanced stage.
  • The median survival after brain metastasis in patients with brain metastasis as first recurrence was longer than the patients with brain metastasis after other organ metastasis (13 months vs 2 months P=.003).
  • The median survival following brain metastases in complete responsive patients was higher than the others (24 months vs 6 months, P=.002).
  • Therefore, response to systemic treatment was more determinative in the development of isolated brain metastases than clinical and pathologic features.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Cranial Irradiation. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Receptor, ErbB-2 / analysis. Retrospective Studies. Treatment Outcome. Turkey


32. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, Charest A: Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A; 2009 Feb 24;106(8):2712-6
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.
  • Glioblastoma multiforme (GBM) is a highly lethal brain tumor for which little treatment is available.
  • The epidermal growth factor receptor (EGFR) signaling pathway is thought to play a crucial role in GBM pathogenesis, initiating the early stages of tumor development, sustaining tumor growth, promoting infiltration, and mediating resistance to therapy.
  • Consistent with this, we show here that concomitant activation of wild-type and/or mutant (vIII) EGFR and ablation of Ink4A/Arf and PTEN tumor suppressor gene function in the adult mouse central nervous system generates a fully penetrant, rapid-onset high-grade malignant glioma phenotype with prominent pathological and molecular resemblance to GBM in humans.
  • Studies of the activation of signaling events in these GBM tumor cells revealed notable differences between wild-type and vIII EGFR-expressing cells.
  • We show that wild-type EGF receptor signals through its canonical pathways, whereas tumors arising from expression of mutant EGFR(vIII) do not use these same pathways.
  • Our findings provide critical insights into the role of mutant EGFR signaling function in GBM tumor biology and set the stage for testing of targeted therapeutic agents in the preclinical models described herein.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72 [17646646.001]
  • [Cites] Cancer Cell. 2007 Jul;12(1):9-22 [17613433.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):745-60 [11484948.001]
  • [Cites] Genesis. 2002 Feb;32(2):148-9 [11857804.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):131-6 [15193025.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9 [1557402.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):636-7 [16079829.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):867-74 [16424019.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71 [16609043.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):120-39 [16889899.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):378-81 [17255257.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):112-6 [17317137.001]
  • [Cites] Science. 2007 Oct 12;318(5848):287-90 [17872411.001]
  • (PMID = 19196966.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL081170; United States / NCI NIH HHS / CA / U54 CA119349; United States / NHLBI NIH HHS / HL / K08HL081170
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2650331
  •  go-up   go-down


33. Bentsion DL, Gvozdev PB, Sakovich VP, Fialko NV, Kolotvinov VS, Baiankina SN: [The first experience in interstitial brachytherapy for primary and metastatic tumors of the brain]. Zh Vopr Neirokhir Im N N Burdenko; 2006 Jan-Mar;(1):18-21; discussion 21
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The first experience in interstitial brachytherapy for primary and metastatic tumors of the brain].
  • In 2001-2002, the authors performed a course of brachytherapy in 15 patients with inoperable primary, recurrent, and metastatic brain tumors.
  • Five patients had solid tumor deposits in the brain.
  • Computer tomographic (CT) and magnetic resonance imaging (MRI) data were used to define a path for forthcoming biopsy and implantation at a "Stryker" navigation station, by taking into account the anatomy of the brain, vessels, and functionally significant areas.
  • After having histological findings, plastic intrastats whose number had been determined by the volume of a target were implanted into a tumor by the predetermined path.
  • The final stage involved irradiation on a "GammaMed plus" with a source of 192Ir.
  • Patients with gliomas untreated with radiation also underwent external radiation in a TFD of 54-56 Gy and patients with brain metastases received total external irradiation of the brain in a TFD of 36-40 Gy.
  • The mean lifespan of patients with malignant gliomas and solid tumor metastasis was 11.5 and 5.8 months, respectively.
  • Brachytherapy is a noninvasive and tolerable mode of radiotherapy that increases survival in some groups of patients with inoperable brain tumors.
  • [MeSH-major] Brachytherapy. Brain Neoplasms / radiotherapy. Glioma / radiotherapy
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739930.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


34. Nicolato A, Ria A, Foroni R, Manno P, Alessandrini F, Sava T, Lupidi F, Leone P, Maluta S, Cetto GL, Gerosa M: Gamma knife radiosurgery in brain metastases from testicular tumors. Med Oncol; 2005;22(1):45-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery in brain metastases from testicular tumors.
  • To our knowledge, there are no published reports on the effectiveness of radiosurgery in the management of brain metastases from testicular nonseminomatous germ cell tumor.
  • Between April 1995 and July 2001, three patients with brain metastasis from testicular nonseminomatous germ cell tumor underwent adjuvant radiosurgery at our department.
  • The primary tumor had been surgically removed in all cases.
  • At diagnosis, one patient was stage IB and two were stage III poor risk.
  • Chemotherapy and whole brain radiotherapy were administered before radiosurgery in all cases.
  • The indications for radiosurgery were tumor volume <20 cm3, microsurgery too risky, refusal of surgery.
  • All the lesions were located in eloquent brain areas.
  • Neuroradiological follow-up invariably showed tumor growth control (complete response in two cases and partial response in one) with typically delayed post-radiosurgical imaging changes (transient in two cases and long-lasting in one).
  • In conclusion, GK seems to be highly effective and safe in brain metastases from testicular nonseminomatous germ cell tumor.
  • In cases with diffuse metastatic brain involvement, the whole brain radiotherapy preceding radiosurgery should be delivered with 1.8 Gy daily fraction to prevent the risk of long-lasting post-radiosurgical imaging changes.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / secondary. Radiosurgery / methods. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15750196.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Onodera H, Nagayama S, Tachibana T, Fujimoto A, Imamura M: Brain metastasis from colorectal cancer. Int J Colorectal Dis; 2005 Jan;20(1):57-61
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis from colorectal cancer.
  • PURPOSE: The mechanism of brain metastasis is not well understood, but the affinity between cancer cells and neural tissues may be involved in the process.
  • The aim of our study is to elucidate the involvement of neural cell adhesion molecule (NCAM) and therapeutic parameters in patients with brain metastasis from colorectal cancer.
  • METHODS: We retrospectively identified 17 patients with brain metastasis from colorectal cancer.
  • Data were collected with regard to patients' characteristics, location, and stage of primary tumor, and extent and location of metastatic disease.
  • RESULTS: Neural cell adhesion molecule expression was significantly higher in the primary tumors of the brain metastasis patients than in the lesions of the Dukes C and Dukes D control groups (p = 0.0004).
  • Patients whose tumor was managed by radiosurgery survived longer than patients who had had whole brain radiation or those who had been left untreated.
  • CONCLUSION: The fact that NCAM expression was high in the primary tumors of brain metastasis patients suggests that the affinity of cancer cells to a particular organ is important for circulation-mediated metastasis.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / secondary. Colorectal Neoplasms / pathology. Neural Cell Adhesion Molecules / biosynthesis. Neural Cell Adhesion Molecules / physiology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Cranial Irradiation. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2001 Sep-Oct;87(5):332-4 [11765184.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1467-71 [10566536.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):541-5 [8620805.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:d477-90 [12456309.001]
  • [Cites] Cancer. 2003 Aug 25;99(4):240-6 [12925986.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1677-85 [10223560.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):709-12 [2703275.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):711-6 [8756361.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):559-64 [8823783.001]
  • [Cites] Science. 1983 Feb 4;219(4584):450-7 [6823544.001]
  • [Cites] Cancer. 2002 May 15;94(10):2698-705 [12173339.001]
  • [Cites] J Cell Biol. 2002 Nov 25;159(4):649-61 [12438412.001]
  • [Cites] Surg Today. 1994;24(1):30-6 [8054772.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):528-32 [12827605.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):345-67 [8823768.001]
  • [Cites] Ann Surg Oncol. 1996 Sep;3(5):453-63 [8876887.001]
  • [Cites] J Neurooncol. 1983;1(3):203-9 [6678969.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):499-506 [12507085.001]
  • (PMID = 15309466.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neural Cell Adhesion Molecules
  •  go-up   go-down


36. Haris M, Gupta RK, Husain N, Hasan KM, Husain M, Narayana PA: Measurement of DTI metrics in hemorrhagic brain lesions: possible implication in MRI interpretation. J Magn Reson Imaging; 2006 Dec;24(6):1259-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of DTI metrics in hemorrhagic brain lesions: possible implication in MRI interpretation.
  • PURPOSE: To understand the biological basis of possible mechanisms responsible for increased fractional anisotropy (FA) in different stages of hemorrhage and hemorrhagic brain lesions.
  • MATERIALS AND METHODS: A total of 19 patients with cerebral hemorrhage (CH), five patients with hemorrhagic infarct (HI), and nine patients with hemorrhagic brain tumor (HBT) were prospectively evaluated with diffusion tensor imaging (DTI) and the FA and mean diffusivity (MD) was quantified.
  • RESULTS: High FA (>0.20) with low MD in the acute and early subacute stage and low FA (<0.20) with increased MD in the late subacute and chronic stage of CH and HI were observed.
  • CONCLUSION: Intact RBCs entangled within fibrin mesh appear to be responsible for high FA in hemorrhagic brain lesions.
  • [MeSH-major] Algorithms. Brain / pathology. Diffusion Magnetic Resonance Imaging / methods. Image Enhancement / methods. Image Interpretation, Computer-Assisted / methods. Intracranial Hemorrhages / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17096394.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Fléchon A, Culine S, Théodore C, Droz JP: Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol; 2005 Dec;48(6):957-63; discussion 963-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of relapse after first line treatment of advanced stage germ-cell tumors.
  • Thirty-five (36.4%) patients had serum tumor marker levels (AFP, hCG and LDH) normal values.
  • Sites of relapse were: abdominal in 47 (49%) patients, thoracic in 17 (17.7%), thoraco-abdominal in 15 (15.6%), and brain in 8 (8.3).
  • All patients with brain metastases at relapse and those who obtained sCR after chemotherapy relapsed within 8 months of follow-up.
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy, Needle. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Follow-Up Studies. France. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Urologic Surgical Procedures, Male / methods

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16084010.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, Englund E, Bengzon J, Jacobsen SE, Nuber UA: CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res; 2007 Jun 15;67(12):5727-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells.
  • Human brain tumor stem cells have been enriched using antibodies against the surface protein CD133.
  • An antibody recognizing CD133 also served to isolate normal neural stem cells from fetal human brain, suggesting a possible lineage relationship between normal neural and brain tumor stem cells.
  • Whether CD133-positive brain tumor stem cells can be derived from CD133-positive neural stem or progenitor cells still requires direct experimental evidence, and an important step toward such investigations is the identification and characterization of normal CD133-presenting cells in neurogenic regions of the embryonic and adult brain.
  • Here, we present evidence that CD133 is a marker for embryonic neural stem cells, an intermediate radial glial/ependymal cell type in the early postnatal stage, and for ependymal cells in the adult brain, but not for neurogenic astrocytes in the adult subventricular zone.
  • Our findings suggest two principal possibilities for the origin of brain tumor stem cells: a derivation from CD133-expressing cells, which are normally not present in the adult brain (embryonic neural stem cells and an early postnatal intermediate radial glial/ependymal cell type), or from CD133-positive ependymal cells in the adult brain, which are, however, generally regarded as postmitotic.
  • Alternatively, brain tumor stem cells could be derived from proliferative but CD133-negative neurogenic astrocytes in the adult brain.
  • In the latter case, brain tumor development would involve the production of CD133.
  • [MeSH-major] Antigens, CD / metabolism. Brain Neoplasms / metabolism. Embryonic Stem Cells / metabolism. Ependyma / metabolism. Glioblastoma / metabolism. Glycoproteins / metabolism. Peptides / metabolism. Prosencephalon / metabolism
  • [MeSH-minor] Adult. Animals. Astrocytes / metabolism. Blotting, Western. Epithelial Cells / metabolism. Flow Cytometry. Fluorescent Antibody Technique. Humans. Mice. Mice, Inbred C57BL. Mice, Transgenic. Neoplastic Stem Cells / metabolism. Neuroglia / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575139.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501838
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


39. Wright G, Shawcross D, Olde Damink SW, Jalan R: Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis; 2007 Dec;22(3-4):375-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension.
  • BACKGROUND: In acute liver failure (ALF), it is unclear whether the systemic inflammatory response associated with intracranial hypertension is related to brain cytokine production.
  • AIM: To determine the relationship of brain cytokine production with severity of intracranial hypertension in ALF patients.
  • In the ALF patients studied longitudinally, brain proinflammatory cytokine production was associated with uncontrolled ICP.
  • CONCLUSION: Our results provide novel data supporting brain production of cytokines in patients with uncontrolled intracranial hypertension indicating activation of the inflammatory cascade in the brain.
  • Also, the appearance of these cytokines in the jugular bulb catheter may indicate a compromised blood brain barrier at this late stage.
  • [MeSH-major] Brain / immunology. Cytokines / biosynthesis. Intracranial Hypertension / etiology. Liver Failure, Acute / immunology
  • [MeSH-minor] Adult. Ammonia / metabolism. Cross-Sectional Studies. Hepatic Encephalopathy / etiology. Humans. Interleukin-1beta / biosynthesis. Interleukin-6 / biosynthesis. Tumor Necrosis Factor-alpha / biosynthesis

  • Genetic Alliance. consumer health - Intracranial Hypertension.
  • Hazardous Substances Data Bank. Ammonia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899343.001).
  • [ISSN] 0885-7490
  • [Journal-full-title] Metabolic brain disease
  • [ISO-abbreviation] Metab Brain Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 7664-41-7 / Ammonia
  •  go-up   go-down


40. Gutenberg A, Schulten HJ, Gunawan B, Ludwig HC, Brück W, Larsen J, Rohde V: CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy. Pediatr Neurosurg; 2009;45(1):61-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy.
  • We present the very unusual case of a young woman suffering from a brain tumor 22 years after a stage IV spinal neuroblastoma as an infant, demonstrating the difficulties of differentiating late neuroblastoma relapse from secondary supratentorial primitive neuroectodermal tumor (sPNET).
  • Lacking specific immunohistochemical features, the first cerebral tumor at the age of 21 was regarded as sPNET, and we pursued a therapeutic approach consisting of neurosurgical resection as well as irradiation and high-dose alkylator-based chemotherapy according to the HIT2000 protocol.
  • Moreover, the lack of PNET-specific translocations (EWS/FLI1 gene fusion) in both brain tumors as well as the development of hepatic metastases was more compatible with the diagnosis of a very late relapse 22 years after initial stage IV spinal neuroblastoma.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genetic Markers. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258732.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


41. Dawood S, Ueno NT, Valero V, Andreopoulou E, Hsu L, Lara J, Woodward W, Buchholz TA, Hortobagyi GN, Cristofanilli M: Incidence of and survival following brain metastases among women with inflammatory breast cancer. Ann Oncol; 2010 Dec;21(12):2348-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of and survival following brain metastases among women with inflammatory breast cancer.
  • BACKGROUND: The purpose of this study was to determine the incidence of and survival following brain metastases among women with inflammatory breast cancer (IBC).
  • PATIENTS AND METHODS: Two hundred and three women with newly diagnosed stage III/IV IBC diagnosed from 2003 to 2008, with known Human epidermal growth factor receptor 2 (HER2) and hormone receptor status, were identified.
  • Cumulative incidence of brain metastases was computed.
  • Multivariable Cox proportional hazards models were fitted to explore the relationship between breast tumor subtype and time to brain metastases.
  • Thirty-two (15.8%) patients developed brain metastases with a cumulative incidence at 1 and 2 years of 2.7% and 18.7%, respectively.
  • Eleven (5.3%) patients developed brain metastases as the first site of recurrence with cumulative incidence at 1 and 2 years of 1.6% and 5.7%, respectively.
  • Compared with women with triple receptor-negative IBC, those with hormone receptor-positive/HER2-negative disease [hazard ratio (HR) = 0.55, 95% confidence interval (CI) 0.19-1.51, P = 0.24] had a decreased risk of developing brain metastases, and those with HER2-positive disease (HR = 1.02, 95% CI 0.43-2.40, P = 0.97) had an increased risk of developing brain metastases, although these associations were not statistically significant.
  • Median survival following a diagnosis of brain metastases was 6 months.
  • CONCLUSION: Women with newly diagnosed IBC have a high early incidence of brain metastases associated with poor survival and may be an ideal cohort to target for site-specific screening.


42. Cao Y, Tsien CI, Nagesh V, Junck L, Ten Haken R, Ross BD, Chenevert TL, Lawrence TS: Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys; 2006 Mar 01;64(3):876-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected].
  • Tumor perfusion was classified as high, medium, or low.
  • The prognostic values of pre-RT perfusion and the changes during RT for early prediction of tumor response to RT were evaluated.
  • RESULTS: The fractional high-CBV tumor volume before RT and the fluid-attenuated inversion recovery imaging tumor volume were identified as predictors for survival (p = 0.01).
  • Changes in tumor CBV during the early treatment course also predicted for survival.
  • Better survival was predicted by a decrease in the fractional low-CBV tumor volume at Week 1 of RT vs. before RT, a decrease in the fractional high-CBV tumor volume at Week 3 vs. Week 1 of RT, and a smaller pre-RT fluid-attenuated inversion recovery imaging tumor volume (p = 0.01).
  • This might also open the opportunity to identify tumor subvolumes that are radioresistant and might benefit from intensified RT.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / radiotherapy. Brain Neoplasms / blood supply. Brain Neoplasms / radiotherapy. Cerebrovascular Circulation. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents / pharmacology. Blood Volume. Brain / blood supply. Brain / radiation effects. Dexamethasone / pharmacology. Female. Glioblastoma / blood supply. Glioblastoma / mortality. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Prognosis. Regression Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):960
  • (PMID = 16298499.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA113699; United States / NCI NIH HHS / CA / R21 CA11369901; United States / NCI NIH HHS / CA / P01 CA85878; United States / NCI NIH HHS / CA / 2 PO1 CA59827
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


43. Souweidane MM, Morgenstern PF, Christos PJ, Edgar MA, Khakoo Y, Rutka JT, Dunkel IJ: Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors. Neurosurgery; 2009 Jul;65(1):72-8; discussion 78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative arachnoid and cerebrospinal fluid sampling in children with posterior fossa brain tumors.
  • OBJECTIVE: This study was conducted to determine whether arachnoid tissue or cerebrospinal fluid (CSF) sampling is valuable for risk stratification in children with posterior fossa brain tumors.
  • METHODS: Arachnoid tissue and CSF from the cisterna magna (CSFCM) was sampled at the time of primary tumor resection.
  • Results were compared with conventional staging methods (M stage) and correlated with patient outcome.
  • Arachnoid infiltration and CSF cytology were found in 20.0% and 44.8%, respectively, for medulloblastoma/pineoblastoma (primitive neuroectodermal tumor), 6.9% and 3.6% for pilocytic astrocytoma, and 0.0% and 33.3% for ependymoma.
  • The 3-year EFS for patients with primitive neuroectodermal tumor who had positive arachnoid sampling was 33.3%, compared with 67.3% in patients who had no evidence of arachnoid infiltration (P = 0.26).
  • The 3-year EFS for patients with primitive neuroectodermal tumor who had positive CSFCM was 50.0% compared with 67.5% in patients who had negative cytological analysis of CSFCM (P = 0.07).
  • Arachnoid infiltration and CSF sampling were congruous with M stage in 73.3% and 86.2% of patients, respectively.
  • CONCLUSION: Intraoperative evidence of arachnoid infiltration or CSFCM dissemination in patients with posterior fossa brain tumors occurs at a variable frequency that is dependent on tumor type, correlates with conventional M stage, and may be predictive of outcome.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574827.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Shrestha P, Saito T, Hama S, Arifin MT, Kajiwara Y, Yamasaki F, Hidaka T, Sugiyama K, Kurisu K: Geminin: a good prognostic factor in high-grade astrocytic brain tumors. Cancer; 2007 Mar 1;109(5):949-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geminin: a good prognostic factor in high-grade astrocytic brain tumors.
  • For this study, the authors investigated geminin expression in high-grade astrocytic tumors, including anaplastic astrocytoma (AA) and glioblastoma multiforme (GBM), with a view to predicting clinical outcomes on this basis in patients with these malignant brain tumors.
  • The relation of geminin expression to clinical outcome in these malignant brain tumors was analyzed by using the Kaplan-Meier method and a Cox proportional hazards regression model.
  • Similarly, the Cox regression analysis showed that geminin expression has a significant correlation with survival in patients with high-grade astrocytoma (P = .0278), especially in an early stage.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cell Cycle Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Female. Geminin. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17262828.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GMNN protein, human; 0 / Geminin
  •  go-up   go-down


45. Lehnhardt FG, Bock C, Röhn G, Ernestus RI, Hoehn M: Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed; 2005 Oct;18(6):371-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation.
  • Spectroscopic features of tumor types, as determined on samples of the primary occurrences, were in good agreement with previous studies.
  • Metabolic changes of an evolving tumor were observed in recurrent astrocytomas: owing to their consecutive assessments, more indicators of malignant degeneration were detected in astrocytoma recurrences (e.g.
  • The present investigation demonstrated a correlation of the tCho-signal with tumor progression.
  • This may be related to an early stage of malignant transformation, not yet detectable morphologically, and emphasizes the high sensitivity of 1H NMR spectroscopy in elucidating characteristics of brain tumor metabolism.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Glioblastoma / metabolism. Magnetic Resonance Spectroscopy / methods. Meningioma / metabolism. Neoplasm Recurrence, Local / metabolism
  • [MeSH-minor] Adult. Humans. Middle Aged. Protons

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 John Wiley & Sons, Ltd
  • (PMID = 15959923.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


46. Kruser TJ, Chao ST, Elson P, Barnett GH, Vogelbaum MA, Angelov L, Weil RJ, Pelley R, Suh JH: Multidisciplinary management of colorectal brain metastases: a retrospective study. Cancer; 2008 Jul 1;113(1):158-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary management of colorectal brain metastases: a retrospective study.
  • BACKGROUND: The incidence of brain metastases (BM) from colorectal cancer (CRC) is increasing, and the management of this previously rare complication at a single institution is reported.
  • Associations between patient and tumor characteristics, treatment modality, and survival were assessed.
  • Fifteen patients (31%) underwent surgery at some point, 14 patients (29%) underwent stereotactic radiosurgery (SRS), and 42 patients (86%) received whole-brain radiotherapy during their management.
  • Sex, Karnofsky performance status, tumor location, recursive partitioning analysis class, and initial treatment modality did not have an impact on survival.
  • CONCLUSIONS: Because BM from CRC are a late-stage phenomenon, the majority of patients in the current study had other systemic involvement, and survival after CNS involvement was poor.
  • Late development (>1 year after the primary tumor diagnosis) of CNS involvement may predict for poorer survival after therapy for patients with BM from CRC.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / therapy. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Cranial Irradiation. Female. Humans. Male. Middle Aged. Prognosis. Radiosurgery. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18459179.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA009614-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Melanoma Study Group of the Mayo Clinic Cancer Center, Celis E: Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer; 2007 Jul 1;110(1):203-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
  • METHODS: Patients with stage IV melanoma were randomized to 1 of 3 treatment arms:.
  • Exclusion criteria included pregnancy/nursing, brain metastases, and ongoing chemotherapy.
  • RESULTS: None of the 28 patients exhibited objective tumor responses or severe toxicities.
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Dendritic Cells / immunology. Epitopes / immunology. Female. Freund's Adjuvant / chemistry. Granulocyte-Macrophage Colony-Stimulating Factor / chemistry. HLA Antigens / immunology. Humans. Lymphocyte Activation / drug effects. Lymphocyte Activation / immunology. Male. Mannitol / analogs & derivatives. Mannitol / chemistry. Middle Aged. Neoplasm Staging. Oleic Acids / chemistry. Survival Analysis. Survival Rate. T-Lymphocytes, Cytotoxic / drug effects. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17541944.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Epitopes; 0 / GRAMLGTHTMEVTV; 0 / HLA Antigens; 0 / Oleic Acids; 0 / Oligopeptides; 0 / montanide ISA 51; 3OWL53L36A / Mannitol; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9007-81-2 / Freund's Adjuvant
  •  go-up   go-down


48. Atahan IL, Ozyigit G, Yildiz F, Gurkaynak M, Selek U, Sari S, Hayran M: Percent positive axillary involvement predicts for the development of brain metastasis in high-risk patients with nonmetastatic breast cancer receiving post-mastectomy radiotherapy. Breast J; 2008 May-Jun;14(3):245-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percent positive axillary involvement predicts for the development of brain metastasis in high-risk patients with nonmetastatic breast cancer receiving post-mastectomy radiotherapy.
  • We retrospectively assessed the predictive factors for brain metastasis in high-risk breast cancer patients receiving radiotherapy after mastectomy.
  • The clinical and pathologic features of patients who developed brain metastasis as the first site metastatic disease were compared with nonmetastatic patients treated at the same time period.
  • Age, stage, percent positive lymph node involvement, number of lymph node metastasis, primary tumor size, grade, surgical margin status, estrogen receptor status, and perinodal fat tissue invasion were analyzed as predictive factors for brain metastasis.
  • In this period, 32 out of 957 patients (3.3%) developed brain metastasis.
  • In univariate analysis percent positive axillary lymph node involvement (p < 0.001), primary tumor size (p < 0.001), number of lymph node metastasis (p = 0.01), and American Joint Committee on Cancer 2002 stage (p < 0.001) were found to be predictive for brain metastasis.
  • Multivariate analysis revealed that only the primary tumor size and percent positive lymph node involvement were significant predictive factors for the development of brain metastasis.
  • The primary tumor size and percent positive lymph node involvement increases the risk of brain metastasis in patients with nonmetastatic breast cancer receiving postoperative radiotherapy and chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / therapy. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Axilla. Female. Humans. Lymphatic Metastasis. Mastectomy. Neoplasm Staging. Predictive Value of Tests. Radiotherapy. Retrospective Studies. Survival Analysis


49. Wang YX, King AD, Zhou H, Leung SF, Abrigo J, Chan YL, Hu CW, Yeung DK, Ahuja AT: Evolution of radiation-induced brain injury: MR imaging-based study. Radiology; 2010 Jan;254(1):210-8
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of radiation-induced brain injury: MR imaging-based study.
  • PURPOSE: To evaluate the temporal lobes in patients previously treated for nasopharyngeal carcinoma to provide a better understanding of delayed radiation-induced injury in the brain unaffected by the underlying tumor.
  • Cysts are the least frequent manifestation and arise in the late stage of TLI.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Contrast Media. Female. Gadolinium. Humans. Male. Middle Aged. Nasopharyngeal Neoplasms / radiotherapy. Retrospective Studies. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20019142.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


50. Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN: Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer; 2009 Jan 1;115(1):119-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
  • Therefore, in patients with metastatic melanoma, the combination of chemotherapy with an agent that specifically targets VEGF might be able to control tumor growth and progression more effectively than chemotherapy alone.
  • METHODS: A 2-stage phase 2 clinical trial was conducted in patients with unresectable stage IV (metastatic) melanoma to assess antitumor activity and the toxicity profile of the combination of carboplatin (area under the curve 6 iv on Day 1 of a 28-day cycle), paclitaxel (80 mg/m2 iv on Days 1, 8, and 15), and bevacizumab (10 mg/kg iv on Days 1 and 15).
  • One patient died after 8 treatment cycles from intracranial hemorrhage into undiagnosed brain metastases.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2992-8 [18565886.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):527-34 [18235113.001]
  • [Cites] J Invest Dermatol. 2000 Dec;115(6):1000-7 [11121133.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):577-83 [11208853.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1904-13 [11535528.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Feb;11(1):103-18 [11847007.001]
  • [Cites] Am J Clin Oncol. 2002 Jun;25(3):283-6 [12040289.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):208-24 [12539175.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3172-9 [12789293.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2933-9 [12885812.001]
  • [Cites] Melanoma Res. 2003 Oct;13(5):531-6 [14512795.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):821-4 [14871806.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2092-100 [15123733.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Oct;18(5):951-71, vii [15474329.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Br J Cancer. 1997;76(7):930-4 [9328154.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4185-92 [9751633.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):375-84 [10027396.001]
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1151-61 [15610528.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3706-12 [15867200.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7785-93 [16258082.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):375-82 [16342250.001]
  • [Cites] Pathology. 2006 Apr;38(2):132-7 [16581653.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4331-8 [16857808.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2367-76 [17534686.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9 [17686822.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • (PMID = 19090009.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR000585-332075; United States / NCI NIH HHS / CA / U10 CA035267; United States / NCRR NIH HHS / RR / M01 RR000585; United States / NCRR NIH HHS / RR / M01 RR000585-342075; United States / NCI NIH HHS / CA / U10 CA052352; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA035269; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-35195; United States / NCRR NIH HHS / RR / M01 RR000585-332075; United States / NCRR NIH HHS / RR / RR000585-342075; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / U10 CA063849; United States / NCRR NIH HHS / RR / M01 RR000585-332026; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCRR NIH HHS / RR / RR000585-332026; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / U10 CA035103
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS87623; NLM/ PMC2718695
  •  go-up   go-down


51. Chuang KL, Liaw CC, Ueng SH, Liao SK, Pang ST, Chang YH, Chuang HC, Chuang CK: Mixed germ cell tumor metastatic to the skin: case report and literature review. World J Surg Oncol; 2010;8:21
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed germ cell tumor metastatic to the skin: case report and literature review.
  • Other metastatic sites include the lung, liver, brain, adrenal glands, gastrointestinal tract and spleen.
  • CASE PRESENTATION: A 19-year old male was diagnosed testicular mixed germ cell tumor with initial presentation of cutaneous metastasis at scalp and upper abdomen.
  • CONCLUSIONS: For advanced stage testicular cancer, cisplatin-based chemotherapy is still effective to achieve partial response.
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2001 Feb;67(2):117-20 [11236220.001]
  • [Cites] Clin Exp Dermatol. 2002 Jan;27(1):64-5 [11952675.001]
  • [Cites] Int J Urol. 2003 Feb;10(2):103-4 [12588608.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 May;18(3):386-7 [15096171.001]
  • [Cites] Urology. 2004 Jun;63(6):1021-6 [15183939.001]
  • [Cites] J Cutan Pathol. 2004 Jul;31(6):419-30 [15186430.001]
  • [Cites] J Cutan Pathol. 2010 Apr;37(4):486-90 [19469863.001]
  • [Cites] Vopr Onkol. 1981;27(4):70-3 [7195101.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):548-51 [6284333.001]
  • [Cites] Hinyokika Kiyo. 1983 Feb;29(2):155-68 [6687145.001]
  • [Cites] Cutis. 1987 Feb;39(2):119-21 [3829718.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Urology. 2006 Apr;67(4):846.e15-7 [16600346.001]
  • [Cites] J Urol. 1976 Nov;116(5):593-7 [988197.001]
  • (PMID = 20331874.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2851696
  •  go-up   go-down


52. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA: Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res; 2005 Sep-Oct;25(5):3553-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature.
  • BACKGROUND: Brain metastases from epithelial ovarian cancer (EOC) are rare.
  • A retrospective study of all patients diagnosed with brain metastases from EOC over the last 20 years, according to the Hellenic Cooperative Oncology Group (HeCOG) tumor registry, was conducted.
  • Seventeen (1.17%) of them developed brain metastases.
  • RESULTS: The median age at diagnosis of brain metastases was 58 years (range, 24 to 77).
  • At initial diagnosis, 2 patients had stage II, 12 had stage III and 3 had stage IV disease.
  • Two (12%) patients with isolated single brain lesions underwent surgical excision of the metastases, followed by whole brain radiation therapy (WBRT) and chemotherapy.
  • Four (24%) patients were treated with WBRT alone, 6 (35%) patients with WBRT plus chemotherapy and 2 (12%) had only supportive care, while 3 (18%) patients decided not to have any further treatment after the diagnosis of brain metastases.
  • The prognosis of patients with brain metastases from EOC is poor.
  • [MeSH-major] Brain Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Survival Rate


53. Yang SY, Kim DG, Lee SH, Chung HT, Paek SH, Hyun Kim J, Jung HW, Han DH: Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer; 2008 Apr 15;112(8):1780-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases.
  • BACKGROUND: The aim of the current study was to determine whether a pulmonary resection and gamma-knife radiosurgery (GKRS) protocol is superior to GKRS alone in selected patients with stage IV nonsmall-cell lung cancer (NSCLC).
  • METHODS: The authors performed a retrospective case-control study of 232 consecutive patients with newly diagnosed NSCLC from January 1998 to December 2005 and screened them to identify a study cohort in which all patients had thoracic stage I or II, Karnofsky performance status >or= 70, no extracranial metastases, and 1-3 synchronous brain metastases of less than 3 cm, and were treated with GKRS (n=31).
  • One-year and 5-year local brain tumor control rates were 97.1% and 93.5%, respectively.
  • CONCLUSIONS: The pulmonary resection and GKRS protocol could prolong survival in patients with thoracic stage I or II NSCLC, no extracranial metastases, and a limited number of small synchronous brain metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Retrospective Studies. Survival Rate


54. da Silva RL, Resende RR, Ulrich H: Alternative splicing of P2X6 receptors in developing mouse brain and during in vitro neuronal differentiation. Exp Physiol; 2007 Jan;92(1):139-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternative splicing of P2X6 receptors in developing mouse brain and during in vitro neuronal differentiation.
  • P2X receptor expression, mainly of P2X(4) and P2X(6) subtypes, has been detected in adult brain and also during neuronal development.
  • The alternatively spliced form was already present at the stage of pluripotent undifferentiated P19 cells, and was predominant compared to the full-length form during the whole course of neuronal differentiation of P19 cells.
  • Alternative splicing of P2X(6) receptor subunits was also confirmed during postnatal development of mouse brain.
  • [MeSH-major] Alternative Splicing. Brain / metabolism. Cell Differentiation. Gene Expression Regulation, Developmental. Neurons / metabolism. Receptors, Purinergic P2 / metabolism
  • [MeSH-minor] Aging / metabolism. Animals. Base Sequence. Cell Line, Tumor. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Protein Isoforms / metabolism. RNA, Messenger / metabolism. Rats. Rats, Wistar. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259301.001).
  • [ISSN] 0958-0670
  • [Journal-full-title] Experimental physiology
  • [ISO-abbreviation] Exp. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / purinoceptor P2X6
  •  go-up   go-down


55. Kumabe T, Fujimura M, Jokura H, Tominaga T: Surgical treatment for choroid plexus tumors in the fourth ventricle: brain stem infiltration hinders total extirpation. Neurosurg Rev; 2008 Apr;31(2):165-72; discussion 172
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for choroid plexus tumors in the fourth ventricle: brain stem infiltration hinders total extirpation.
  • Preoperative T2-weighted magnetic resonance imaging showed a diffuse high-intensity lesion in the brain stem in four patients.
  • Intraoperative bleeding was well controlled in all five patients by cauterizing the feeding arteries at the early stage of surgery through the telovelar approach.
  • No patient suffered tumor progression within the follow-up of 24-129 months (mean 64 months).
  • Adjuvant therapy for choroid plexus tumors with brain stem infiltration must be established.
  • [MeSH-major] Brain Stem / pathology. Carcinoma / surgery. Cerebral Ventricle Neoplasms / surgery. Choroid Plexus Neoplasms / surgery. Fourth Ventricle / surgery. Neurosurgical Procedures. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adult. Cerebral Hemorrhage / therapy. Child, Preschool. Female. Humans. Intraoperative Complications / therapy. Laminectomy. Magnetic Resonance Imaging. Male. Pregnancy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2002 Apr;57(2):123-6 [12125972.001]
  • [Cites] No Shinkei Geka. 2006 Jan;34(1):73-81 [16440700.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):257-64 [11213963.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):563-6 [1383866.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] No Shinkei Geka. 1997 Sep;25(9):853-7 [9300457.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Neurosurgery. 2006 Apr;58(4 Suppl 2):ONS-202-6; discussion ONS-206-7 [16582641.001]
  • [Cites] J Neurosurg. 1975 Aug;43(2):225-32 [1185253.001]
  • [Cites] No Shinkei Geka. 1991 Jan;19(1):21-6 [2000153.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] Acta Neurochir (Wien). 2005 Feb;147(2):137-42; discussion 142 [15605202.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):303-9 [11220372.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3 Suppl):S7-27 [10983303.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84 [8869156.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • (PMID = 17912563.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


56. Prasanna VK, Venkataramana NK, Dwarakanath BS, Santhosh V: Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma. J Cancer Res Ther; 2009 Sep;5 Suppl 1:S44-7
Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma.
  • 2-Deoxy-D-glucose (2-DG), an inhibitor of glucose transport and glycolysis, enhances radiation damage selectively in tumor cells by modulating damage response pathways resulting in cell death in vitro and local tumor control.
  • Phase III efficacy trials are currently at an advanced stage.
  • Re-exploratory surgery performed in 13 patients due to persistent symptoms of elevated ICP and mass effect at different follow-up periods revealed extensive tumor necrosis with well-preserved normal brain tissue adjoining the tumor included in the treatment volume as revealed by a histological examination.
  • These observations are perhaps the first clinical evidences for differential effects of 2-DG on tumors and normal tissues in conformity with earlier in vitro and in vivo studies in normal and tumor-bearing mice.
  • [MeSH-major] Brain Neoplasms / therapy. Deoxyglucose / therapeutic use. Glioblastoma / therapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Brain / drug effects. Brain / radiation effects. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009294.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 9G2MP84A8W / Deoxyglucose
  •  go-up   go-down


57. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol; 2005 Sep 1;23(25):6043-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
  • We have now treated 56 patients to evaluate two different dose schedules of anti-CTLA-4 and to explore the relationship between autoimmunity and tumor regression.
  • PATIENTS AND METHODS: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study.
  • Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites.
  • [MeSH-minor] Adult. Aged. Antigens, CD. CTLA-4 Antigen. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Male. Middle Aged. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1993 Oct 1;151(7):3489-99 [8397258.001]
  • [Cites] Immunity. 1994 Aug;1(5):405-13 [7882171.001]
  • [Cites] Immunity. 1994 Dec;1(9):793-801 [7534620.001]
  • [Cites] Science. 1995 Nov 10;270(5238):985-8 [7481803.001]
  • [Cites] Nature. 1987 Jul 16-22;328(6127):267-70 [3496540.001]
  • [Cites] Science. 1970 Sep 11;169(3950):1042-9 [4194660.001]
  • [Cites] J Immunol. 2004 Aug 15;173(4):2866-76 [15295006.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5673-7 [14634073.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):666-75 [12951585.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1852-8 [12165509.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2533-40 [8676074.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2541-50 [8676075.001]
  • [Cites] Immunity. 1997 Dec;7(6):885-95 [9430233.001]
  • [Cites] Nat Med. 1998 Mar;4(3):321-7 [9500606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10067-71 [9707601.001]
  • [Cites] Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23 [9815296.001]
  • [Cites] Diabetes. 1999 Mar;48(3):652-7 [10078573.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] J Immunother. 2004 Nov-Dec;27(6):478-9 [15534492.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):741-50 [15613700.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] Genes Immun. 2000 Feb;1(3):170-84 [11196709.001]
  • [Cites] Annu Rev Immunol. 2001;19:565-94 [11244047.001]
  • [Cites] J Exp Med. 2001 Jun 4;193(11):1311-8 [11390438.001]
  • [Cites] Eur J Immunol. 2002 Feb;32(2):366-73 [11807776.001]
  • [Cites] Nat Rev Immunol. 2001 Dec;1(3):220-8 [11905831.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):391-6 [11973140.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):611-8 [12087419.001]
  • [Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):349-56 [12843797.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Science. 1990 Jun 15;248(4961):1349-56 [2113314.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):759-62 [1847724.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):721-30 [1847722.001]
  • [Cites] J Immunol. 1988 May 15;140(10):3324-30 [2834436.001]
  • [Cites] J Exp Med. 1991 Sep 1;174(3):561-9 [1714933.001]
  • [Cites] J Immunol. 1992 Jul 15;149(2):380-8 [1320641.001]
  • [CommentIn] J Clin Oncol. 2005 Sep 1;23(25):5875-7 [16087939.001]
  • (PMID = 16087944.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010763-01; United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cancer Vaccines; 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS10153; NLM/ PMC1473965
  •  go-up   go-down


58. Israelian LA, Lubnin AIu, Cherekaev VA, Belov AI, Arustamian SR: [Prompt massive operative blood loss during removal of a giant parietooccipital tumor in a neurosurgical patient with the single kidney]. Anesteziol Reanimatol; 2006 Mar-Apr;(2):68-73
Hazardous Substances Data Bank. GELATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prompt massive operative blood loss during removal of a giant parietooccipital tumor in a neurosurgical patient with the single kidney].
  • Braun, Germany) at a single-stage infusion volume of 4.5 liters (!
  • ) is described in a neurosurgical patient with the single during removal of a giant parietooccipal tumor complicated by rapid massive operative blood loss.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Brain Neoplasms / surgery. Carcinoma, Renal Cell / surgery
  • [MeSH-minor] Adult. Blood Transfusion, Autologous. Cerebral Angiography. Embolization, Therapeutic. Gelatin / administration & dosage. Hemodilution. Humans. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Male. Nephrectomy. Plasma Substitutes / administration & dosage. Succinates / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758950.001).
  • [ISSN] 0201-7563
  • [Journal-full-title] Anesteziologiia i reanimatologiia
  • [ISO-abbreviation] Anesteziol Reanimatol
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plasma Substitutes; 0 / Succinates; 39340-57-3 / succinylated gelatin; 9000-70-8 / Gelatin
  •  go-up   go-down


59. Monzo M, Moreno I, Artells R, Ibeas R, Navarro A, Moreno J, Hernandez R, Granell M, Pie J: Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett; 2006 Feb 20;233(1):117-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients.
  • Although Shh has been shown to be overexpressed in brain, pancreas, gastric and lung cancers, its role in the development of colorectal cancer has not been examined.
  • We used real-time quantitative PCR to assess Shh mRNA expression levels in tumor and matched normal tissue from 57 colorectal cancer patients and correlated the results with patient clinicopathological characteristics.
  • Shh expression levels were higher in tumor tissue than in normal tissue from the same patient (P=0.00001).
  • Higher levels of Shh expression were associated with early stage disease (P=0.02).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hedgehog Proteins. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473672.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / SHH protein, human; 0 / Trans-Activators
  •  go-up   go-down


60. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA, New Approaches to Brain Tumor Therapy (NABTT) Consortium: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol; 2010 Nov;100(2):261-8
Hazardous Substances Data Bank. Ixabepilone .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.
  • Adult patients received ixabepilone as a 1-h infusion daily for 5 days every 3 weeks.
  • The phase II study used a two-stage design to evaluate response rate.
  • Twenty-three patients (median age 54 years) were enrolled in the first stage of the phase II trial.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6233-9 [16144926.001]
  • [Cites] J Neurooncol. 1999 May;43(1):71-8 [10448874.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):860-8 [16467100.001]
  • [Cites] J Clin Oncol. 2007 Mar 20;25(9):1082-8 [17261851.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):327-34 [17347871.001]
  • [Cites] Ann Oncol. 2007 Jul;18 Suppl 5:v28-34 [17656559.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2701-9 [18451235.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):417-22 [11180089.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1429-37 [11350914.001]
  • [Cites] Drug Metab Dispos. 2002 Jul;30(7):795-804 [12065438.001]
  • [Cites] Drug Metab Dispos. 2003 May;31(5):533-9 [12695340.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1866-73 [12721265.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Drug Metab Dispos. 2004 Mar;32(3):348-58 [14977870.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Eur J Drug Metab Pharmacokinet. 1991 Oct-Dec;16(4):249-55 [1823867.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] J Antibiot (Tokyo). 1996 Jun;49(6):560-3 [8698639.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2316-21 [8708723.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2534-41 [8999970.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3344-6 [9269992.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Clin Oncol. 2005 Sep 20;23(27):6647-56 [16170172.001]
  • [Cites] Clin Pharmacokinet. 2005;44(3):279-304 [15762770.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5294-304 [15998902.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):429-36 [9554585.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] J Clin Pharm Ther. 1999 Apr;24(2):87-92 [10380060.001]
  • [ErratumIn] J Neurooncol. 2010 Nov;100(2):269. Mikkelson, Tom [corrected to Mikkelsen, Tom]
  • (PMID = 20449631.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / UL1 RR025005; United States / NCI NIH HHS / CA / CA62475; United States / NCRR NIH HHS / RR / UL1 RR 025005
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Epothilones; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ NIHMS521307; NLM/ PMC3811044
  •  go-up   go-down


61. Kim YZ, Kim KH, Kim JS, Song YJ, Kim KU, Kim HD: Clinical analysis of patients who survived for less than 3 months after brain metastatectomy. J Korean Med Sci; 2009 Aug;24(4):641-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical analysis of patients who survived for less than 3 months after brain metastatectomy.
  • In the patients with brain metastasis (BM), it is impossible to determine who will benefit from surgery because of limited survival.
  • In an attempt to identify optimal candidates for brain metastatectomy, we analyzed patients who survived for <3 months after craniotomy for a single BM lesion.
  • Of the 25 patients, 19 (79%) were of tumor stage IV and had extra-cranial metastasis.
  • [MeSH-major] Brain Neoplasms / secondary. Brain Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Craniotomy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Neurol (Paris). 1992;148(6-7):477-87 [1448668.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S24-32; discusssion S1-4 [16237284.001]
  • [Cites] J Thorac Cardiovasc Surg. 1996 Jul;112(1):146-53 [8691861.001]
  • [Cites] Neurosurg Clin N Am. 1996 Jul;7(3):337-44 [8823767.001]
  • [Cites] Stereotact Funct Neurosurg. 1996;66 Suppl 1:184-92 [9032860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):53-63 [9407631.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1044-55; discussion 1055-6 [9588549.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1485-9 [9809728.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Sep;122(3):548-53 [11547308.001]
  • [Cites] Lung Cancer. 2001 Aug-Sep;33(2-3):143-54 [11551409.001]
  • [Cites] Neurosurgery. 2003 May;52(5):1066-73; discussion 1073-4 [12699548.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1318-26; discussion 1326 [12762877.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2114-20 [14522368.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1705-11 [15073860.001]
  • [Cites] Adv Neurol. 1978;19:579-92 [570349.001]
  • [Cites] Ann Thorac Surg. 1986 Oct;42(4):360-4 [3767508.001]
  • [Cites] Respiration. 1987;51(3):170-8 [3037658.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):24-8 [3289517.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):494-500 [2405271.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):300-4 [1648994.001]
  • [Cites] Ann Oncol. 1999 Jul;10(7):753-9 [10470420.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S253-7 [15552807.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):31-42 [16215814.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):605-16 [7674008.001]
  • (PMID = 19654946.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2719185
  • [Keywords] NOTNLM ; Brain Metastasis / Metastatectomy / Prognosis / Surgical Candidate / Survival
  •  go-up   go-down


62. Xie SX, Li WX, Huang YJ, Chen JG, Wu YL: [A diagnostic model of cerebrospinal protein fingerprint pattern for brain metastases of non-small cell lung cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar;30(3):498-501
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A diagnostic model of cerebrospinal protein fingerprint pattern for brain metastases of non-small cell lung cancer].
  • OBJECTIVE: To establish a diagnostic model of protein fingerprint pattern in the cerebrospinal fluid (CSF) for non-small-cell lung cancer (NSCLC) patients with brain metastases.
  • METHODS: The CSF samples were obtained from 29 NSCLC patients with brain metastasis, 23 non-tumor patients and 10 early-stage NSCLC patients without brain metastases for analysis of the protein expression profiles using surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS).
  • RESULTS: Five protein peaks were identified showing differential expression between patients with brain metastases and those without brain metastases.
  • Five proteins were differentially expressed between the NSCLC patients with brain metastases and the non-tumor patients.
  • CONCLUSION: The established diagnostic model of CSF protein fingerprint pattern provides high sensitivity and specificity in the diagnosis of NSCLC with brain metastasis.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / cerebrospinal fluid. Carcinoma, Non-Small-Cell Lung / secondary. Cerebrospinal Fluid Proteins / genetics. Peptide Mapping
  • [MeSH-minor] Adult. Aged. Decision Trees. Early Detection of Cancer. Female. Gene Expression Profiling. Humans. Lung Neoplasms / cerebrospinal fluid. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Male. Middle Aged. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335119.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


63. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F: Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis; 2010 Mar;37(3):630-40
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
  • Inflammation, and in particular microglia activation, is regarded as a constant component of brain pathology in Parkinson's disease (PD).
  • Microglial activation has been found in the substantia nigra (SN), one of the main brain regions affected in PD, for many years after the initiation of the disease.
  • For example, tumor necrosis factor-alpha (TNF-alpha), a key pro-inflammatory cytokine, has been shown to exert toxic or no effects on the viability of dopaminergic neurons.
  • The aim of this study was to investigate the effects of the chronic expression of TNF-alpha in the adult SN at different time points.
  • These effects were accompanied by microglial activation to stage 4 and/or monocyte/macrophage recruitment from the periphery from day 7 post adenovector inoculations.
  • In addition, the cellular components of the inflammation elicited by TNF-alpha and the lack of IL-1beta expression support the growing idea of a distinct cytokine network in the brain.
  • [MeSH-major] Encephalitis / metabolism. Microglia / metabolism. Nerve Degeneration / metabolism. Parkinson Disease / metabolism. Substantia Nigra / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Encephalitis.
  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19969084.001).
  • [ISSN] 1095-953X
  • [Journal-full-title] Neurobiology of disease
  • [ISO-abbreviation] Neurobiol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-1beta; 0 / Tumor Necrosis Factor-alpha; VTD58H1Z2X / Dopamine
  •  go-up   go-down


64. Pantazis G, Trippel M, Birg W, Ostertag CB, Nikkhah G: Stereotactic interstitial radiosurgery with the Photon Radiosurgery System (PRS) for metastatic brain tumors: a prospective single-center clinical trial. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1392-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic interstitial radiosurgery with the Photon Radiosurgery System (PRS) for metastatic brain tumors: a prospective single-center clinical trial.
  • PURPOSE: To evaluate the efficacy and the treatment outcome of tumor patients being treated stereotactically with a miniature X-ray generator (Photon Radiosurgery System, PRS).
  • Survival, local control, and distant and overall brain freedom from progression were obtained using the Kaplan-Meier method.
  • Local tumor control at the initial stage and at the last follow-up were 82% and 50%.
  • Eighteen patients (53%) developed distant brain metastases after treatment.
  • At 1 year, the local control rate and distant and overall brain freedom from progression were 33.0%, 43.3%, and 14.7%, respectively.
  • A shorter local tumor control was observed by PRS treatment of a recurrent tumor and by irregular tumor configuration.
  • It allows for an immediate and potentially cost-efficient treatment for patients with singular, small (<or= 6.36 cm(3); or <or= 2.3 cm) spherical brain metastasis subsequent to a stereotactic biopsy.
  • [MeSH-major] Brain Neoplasms / surgery. Photons / therapeutic use. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Amnesia / etiology. Disease Progression. Equipment Design. Female. Gait Disorders, Neurologic / etiology. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Paresis / etiology. Prospective Studies. Radiotherapy Dosage. Remission Induction. Salvage Therapy / methods. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464825.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA: Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer; 2010 Dec 1;55(6):1126-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
  • BACKGROUND: Sorafenib is an inhibitor of multiple kinases (e.g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers.
  • In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75%) of the evaluable solid tumor xenografts and in 1 of 8 (12.5%) of the evaluable ALL xenografts.
  • Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44%) evaluable solid tumor xenografts.
  • The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2004 Dec;12(6):1269-72 [15547749.001]
  • [Cites] Acta Neuropathol. 2004 Dec;108(6):467-70 [15517309.001]
  • [Cites] Leukemia. 2005 Feb;19(2):310-2 [15538400.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35217-27 [16109713.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6861-9 [16007148.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):581-6 [16880785.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):835-44 [17016424.001]
  • [Cites] Am J Pathol. 2006 Nov;169(5):1875-85 [17071608.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11851-8 [17178882.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Haematologica. 2007 Jan;92(1):27-34 [17229632.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74 [17160391.001]
  • [Cites] Leukemia. 2007 Mar;21(3):439-45 [17205056.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):886-97 [17363483.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3363-9 [17545544.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4874-81 [17699867.001]
  • [Cites] Mol Pharmacol. 2007 Sep;72(3):788-95 [17595328.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):37-45 [17420992.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48 [18026728.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):581-7 [17457854.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 6;100(3):184-98 [18230792.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):42-8 [18293383.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6109-17 [18676833.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4908-14 [18676765.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Mol Cancer Ther. 2008 Oct;7(10):3129-40 [18852116.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3519-26 [19001435.001]
  • [Cites] Leuk Res. 2009 Feb;33(2):348-50 [18573526.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6567-71 [19389879.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4263-9 [19549778.001]
  • [Cites] Blood. 2010 Feb 18;115(7):1425-32 [20007803.001]
  • [Cites] Blood. 2010 Mar 25;115(12):2372-9 [20056794.001]
  • [Cites] Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):361-6 [21816375.001]
  • [Cites] Hematol J. 2002;3(3):157-63 [12111653.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • (PMID = 20672370.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CM / N01-CM-42216; United States / NCI NIH HHS / CA / N01CM42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS214707; NLM/ PMC3823056
  •  go-up   go-down


66. Momose T: [Positron emission tomography with FDG and newly developed tracers for the assessment of brain metabolism and synaptic function in neurological disorders]. Brain Nerve; 2007 May;59(5):495-501
MedlinePlus Health Information. consumer health - Neurologic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography with FDG and newly developed tracers for the assessment of brain metabolism and synaptic function in neurological disorders].
  • Positron emission tomography has enabled us to measure various fundamental parameters of human brain physiology and chemistry, such as cerebral blood flow, metabolism and synaptic functions.
  • Glucose metabolism is tightly coupled with brain function and FDG-PET is useful for the determination of epileptic foci and for the evaluation of tumor malignancy.
  • In early stage of Parkinson's disease, only presynaptic dopaminergic function is impaired, while in multiple system atrophy with striato-nigral degeneration type, both pre-and post dopaminergic function is reduced.
  • [MeSH-major] Brain / metabolism. Fluorodeoxyglucose F18. Nervous System Diseases / radionuclide imaging. Positron-Emission Tomography / methods. Synaptic Transmission / physiology
  • [MeSH-minor] Adult. Brain Neoplasms / radionuclide imaging. Epilepsy / radionuclide imaging. Female. Humans. Parkinsonian Disorders / radionuclide imaging

  • Genetic Alliance. consumer health - Neurological Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533975.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 16
  •  go-up   go-down


67. Kong DS, Lee JI, Nam DH, Park K, Kim JH, Kim JG, Park JO, Park K: Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci; 2006 Jun;21(3):527-32
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery.
  • The clinical outcome and prognostic factors of patients with synchronous brain metastases from non-small cell lung cancer (NSCLC) who were treated with gamma knife radiosurgery (GKS) were analyzed.
  • A total of 35 patients with NSCLC underwent GKS as an initial treatment for metastatic brain lesions of synchronous onset.
  • The period of survival and various prognostic factors such as age, gender, performance status, multiplicity of the brain lesions, intracranial tumor volume, and extent of the primary tumor were analyzed.
  • Multivariate analysis of these data revealed that N stage, whole-brain radiotherapy (WBRT), and chemotherapy were significant predictors for survival (p<0.05).
  • Survival of patients with NSCLC and synchronous brain metastases is mainly dependent upon the progression of the systemic disease, provided that the cerebral lesions are treated adequately with local treatment modalities including radiosurgery.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / diagnosis. Lung Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Time Factors. Treatment Outcome


68. Park SK, Yi HJ, Paik SS, Kim YJ, Ko Y, Oh SJ: Metastasizing malignant peripheral nerve sheath tumor initially presenting as intracerebral hemorrhage. Case report and review of the literature. Surg Neurol; 2007 Jul;68(1):79-84; discussion 84
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasizing malignant peripheral nerve sheath tumor initially presenting as intracerebral hemorrhage. Case report and review of the literature.
  • BACKGROUND: Malignant peripheral nerve sheath tumors, infrequent sarcomas arising within a peripheral nerve, mostly metastasize to the lung at terminal stage of disease.
  • However, metastasis to the brain without pulmonary involvement is quite unlikely to occur.
  • The MPNST actually can exhibit an apoplectic manifestation even without pulmonary involvement in a young adult, albeit this is quite rare.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Cerebral Hemorrhage / etiology. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / secondary. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Adult. Craniotomy. Fatal Outcome. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586234.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


69. Daveau C, Stevens D, Brain E, Berges O, Villette S, Moisson P, Gardner M, De la Lande B, Lasry S, Labib A, Le Scodan R: Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy? Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):337-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is regional lymph node irradiation necessary in stage II to III breast cancer patients with negative pathologic node status after neoadjuvant chemotherapy?
  • Survival was poorer among patients who did not have a pathologic complete primary tumor response (hazard ratio, 3.05; 95% confidence interval, 1.17-7.99) and in patients with N1 to N2 clinical status at diagnosis (hazard ratio = 2.24; 95% confidence interval, 1.15-4.36).
  • [MeSH-minor] Adult. Aged. Anthracyclines / therapeutic use. Axilla. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Staging. Radiotherapy Dosage. Regression Analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171795.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines
  •  go-up   go-down


70. Krown SE, Niedzwiecki D, Hwu WJ, Hodgson L, Houghton AN, Haluska FG, Cancer and Leukemia Group B: Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer; 2006 Oct 15;107(8):1883-90
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
  • To confirm these observations the combination was tested in a multicenter Phase II trial in patients with melanoma brain metastases.
  • METHODS: Eligible patients had melanoma brain metastases, with or without systemic metastases.
  • The primary endpoint was response rate in brain metastases.
  • A 2-stage design required > or = 3 responses in the first 21 patients before enrolling 29 additional patients in the second stage.
  • Seven patients withdrew because of tumor progression; 7 were removed during Cycle 1 because of adverse events, including allergic reaction (1 patient), severe fatigue (1 patient), sudden death (1 patient), and thromboembolic events (pulmonary embolism in 3 patients and deep vein thrombosis in 1 patient); 2 patients withdrew when the study was suspended and subsequently closed.
  • These observations provide little support for the use of this combination for melanoma brain metastases unless safe and effective methods to prevent thrombosis are developed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Dacarbazine / analogs & derivatives. Melanoma / drug therapy. Melanoma / secondary. Thalidomide / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Pulmonary Embolism / chemically induced. Skin Neoplasms / pathology. Survival Rate. Treatment Failure. Venous Thrombosis / chemically induced. Withholding Treatment

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16986123.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA12449; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77651
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


71. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, Lacombe D, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor Group Study: Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol; 2008 Oct 1;26(28):4659-65
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
  • Trial design was one-stage Fleming; both an objective response and 6 months of progression-free survival (PFS) were considered a successful outcome to treatment.

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92 [12604685.001]
  • [Cites] Curr Biol. 2001 Feb 20;11(4):232-41 [11250151.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1732-4 [14630677.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Nature. 1983 Jun 2-8;303(5916):390-6 [6304520.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):381-9 [8106574.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):164-71 [8548759.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):771-6 [9815748.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] Clin Pharmacol Ther. 2006 Aug;80(2):192-201 [16890580.001]
  • [Cites] Oncogene. 2006 Aug 10;25(35):4913-22 [16547494.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):432-8 [17312388.001]
  • [Cites] Neurosurgery. 2001 Apr;48(4):864-73; discussion 873-4 [11322447.001]
  • [Cites] Genes Dev. 2001 Aug 1;15(15):1913-25 [11485986.001]
  • [Cites] Ann Oncol. 2002 May;13(5):777-80 [12075748.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1348-50 [12091065.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503 [10850862.001]
  • (PMID = 18824712.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-32; United States / NCI NIH HHS / CA / 5U10 CA11488-33; United States / NCI NIH HHS / CA / 5U10 CA11488-34
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC2653126
  •  go-up   go-down


72. Bruggink AH, de Jonge N, van Oosterhout MF, Van Wichen DF, de Koning E, Lahpor JR, Kemperman H, Gmelig-Meyling FH, de Weger RA: Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant; 2006 Feb;25(2):174-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device.
  • BACKGROUND: Brain natriuretic peptide (BNP) is a cardiac neurohormone synthesized in cardiac ventricles as a result of increased wall stress.
  • Left ventricular assist device (LVAD) support in patients with end-stage heart failure results in reduced wall stress and therefore may change BNP levels in the heart.
  • METHODS: BNP plasma levels were measured in 17 patients with end-stage HF before LVAD implantation and at 1 week, 1 month, and 3 months after LVAD support.
  • [MeSH-major] Heart Failure / metabolism. Heart Failure / therapy. Heart Ventricles / physiopathology. Heart-Assist Devices. Myocardium / chemistry. Myocardium / metabolism. Natriuretic Peptide, Brain / blood
  • [MeSH-minor] Adult. Antigens, CD45 / analysis. Biopsy. Endothelium, Vascular / metabolism. Female. Gene Expression Regulation. Humans. Immunohistochemistry. Macrophages / metabolism. Male. Middle Aged. Myocytes, Cardiac / metabolism. Polymerase Chain Reaction. RNA, Messenger / analysis. RNA, Messenger / genetics. T-Lymphocytes / chemistry. T-Lymphocytes / immunology. T-Lymphocytes / metabolism. T-Lymphocytes / pathology. Tumor Necrosis Factor-alpha / analysis. Tumor Necrosis Factor-alpha / physiology. Ventricular Remodeling / physiology

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16446217.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 114471-18-0 / Natriuretic Peptide, Brain; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


73. Tomita N, Kodaira T, Matsuo M, Furutani K, Tachibana H, Daimon T, Shimizu H: Helical tomotherapy for solitary lung tumor: feasibility study and dosimetric evaluation of treatment plans. Technol Cancer Res Treat; 2010 Aug;9(4):407-15
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helical tomotherapy for solitary lung tumor: feasibility study and dosimetric evaluation of treatment plans.
  • Nine patients with stage IA non-small-cell lung cancer (NSCLC) and three patients with solitary lung metastasis were treated with HT.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / radiotherapy. Radiation Pneumonitis / radiotherapy. Radiotherapy Planning, Computer-Assisted. Tomography, Spiral Computed / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20626206.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO: High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol; 2005 Dec;40(12):743-53
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
  • MATERIALS AND METHODS: In a prospective study, 41 patients withoncologic diseases underwent [F]-fluoro-2-deoxy-D-glucose PET-CT for tumor staging and WB-MRI on a 32-channel-scanner with the use of PAT.
  • Coronal T1w and STIR sequences at 5 body levels, axial HASTE imaging of the lung, and contrast-enhanced T1w sequences of the liver, brain, and abdomen were performed.
  • TNM stage was assessed for both modalities in a separate consensus reading using histologic results and radiologic follow up within 6 months as the standard of reference.
  • RESULTS: Three primary and 4 recurrent tumors were detected; one recurrent tumor was missed with WB-MRI.
  • CONCLUSION: WB-MRI and PET-CT are reliable imaging modalities for tumor staging.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement / methods. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304476.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Allen J, Donahue B, Mehta M, Miller DC, Rorke LB, Jakacki R, Robertson P, Sposto R, Holmes E, Vezina G, Muraszko K, Puccetti D, Prados M, Chan KW: A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1006-11
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
  • METHODS AND MATERIALS: Eligibility criteria included age >3 years at diagnosis, medulloblastoma with either high M stage and/or >1.5 cm(2) postoperative residual disease, and all patients with noncerebellar PNET.
  • Treatment was initiated with five alternating monthly cycles of CHT (A [cisplatin, cyclophosphamide, etoposide, and vincristine], B [carboplatin and etoposide], A, B, and A) followed by hyperfractionated CSRT (40 Gy) with a boost to the primary tumor (72 Gy) given in twice-daily 1-Gy fractions.
  • No significant differences were detected in subset analysis related to response to CHT, site of primary tumor, postoperative residual disease, or M stage.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):279-85 [10030250.001]
  • [Cites] Klin Padiatr. 1998 Jul-Aug;210(4):227-33 [9743957.001]
  • [Cites] Cancer J. 2004 Nov-Dec;10(6):386-90 [15701271.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):727-34 [15763649.001]
  • [Cites] Australas Radiol. 2005 Aug;49(4):298-303 [16026436.001]
  • [Cites] Acta Oncol. 2005;44(6):554-62 [16165914.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):711-6 [15927408.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4202-8 [16943538.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):269-79 [10661332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1287-94 [11483340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Feb;8(2):219-26 [7085377.001]
  • [Cites] Cancer. 1983 Dec 1;52(11):2001-6 [6627214.001]
  • [Cites] J Clin Oncol. 1988 Apr;6(4):649-53 [3258630.001]
  • [Cites] J Clin Oncol. 1989 Jun;7(6):754-60 [2715805.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Fall;12(3):297-300 [2173440.001]
  • [Cites] Cancer. 1993 Nov 1;72(9):2755-62 [8402500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):371-8 [7836091.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1377-83 [7751882.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2247-54 [7666082.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):1155-61 [8985038.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):798-804 [9264364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):15-24 [9300735.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • (PMID = 19356859.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA003888-44; United States / NCI NIH HHS / CA / U10 CA003888; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA003888-44
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS128135; NLM/ PMC2739055
  •  go-up   go-down


76. Swinnen LJ, Rankin C, Carraway H, Albain KS, Townsend JJ, Budd GT, Kish JA, Rivkin SE, Blumenthal DT: A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol; 2008 Feb;86(3):353-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149).
  • The GBM stratum registered 56 patients in a two-stage accrual.
  • Although benefit might be possible in a more platinum-sensitive tumor type, further clinical trials with this regimen for patients with glioblastoma multiforme or anaplastic astrocytoma are not justified.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1485-91 [12697871.001]
  • [Cites] Semin Oncol. 1992 Jun;19(3 Suppl 9):102-9 [1641650.001]
  • [Cites] Biochim Biophys Acta. 1977 Sep 6;478(1):1-8 [407935.001]
  • [Cites] Mutat Res. 1978 Jul;51(1):121-32 [672924.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Mol Pharmacol. 1979 Mar;15(2):367-74 [470933.001]
  • [Cites] Cancer Res. 1980 Sep;40(9):3286-92 [7427943.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Aug;77(8):4602-6 [6254032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Aug;78(8):5132-6 [6975478.001]
  • [Cites] Gan. 1981 Aug;72(4):627-30 [7030860.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2474-9 [6280860.001]
  • [Cites] Mol Pharmacol. 1984 Mar;25(2):322-6 [6700578.001]
  • [Cites] Mutat Res. 1984 Mar-Apr;131(3-4):163-72 [6717470.001]
  • [Cites] J Neurooncol. 1983;1(2):145-7 [6088711.001]
  • [Cites] J Neurooncol. 1984;2(1):29-34 [6088723.001]
  • [Cites] Biochem Pharmacol. 1985 Jul 15;34(14):2557-60 [4015697.001]
  • [Cites] Cancer Res. 1985 Sep;45(9):4178-84 [3928152.001]
  • [Cites] Mutat Res. 1986 Jan;173(1):13-8 [3510378.001]
  • [Cites] Semin Oncol. 1986 Mar;13(1):38-45 [3513316.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):62-6 [2826716.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1383-9 [2924295.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;27(1):33-40 [2245491.001]
  • [Cites] J Bacteriol. 1973 Dec;116(3):1247-52 [4584807.001]
  • (PMID = 18175205.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA28862; United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / U10 CA063845; United States / NCI NIH HHS / CA / U10 CA063850; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / P01 CA053996; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA52772; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035261; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / CA46113; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA052654; United States / NCI NIH HHS / CA / CA76429; United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS591247; NLM/ PMC4051205
  •  go-up   go-down


77. Oh HK, Chambers MS, Martin JW, Lim HJ, Park HJ: Osteoradionecrosis of the mandible: treatment outcomes and factors influencing the progress of osteoradionecrosis. J Oral Maxillofac Surg; 2009 Jul;67(7):1378-86
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The patients whose ORN was associated with an early-stage tumor or preirradiation extraction had a favorable response to conservative treatment.
  • However, those who had an advanced primary tumor, had continued smoking and drinking after radiotherapy, had received palliative radiotherapy or a radiation dose of more than 6,000 rads, and who had an orocutaneous fistula, a pathologic fracture, swelling, or trismus had a poor response to conservative treatment.
  • CONCLUSIONS: The results of the present study have indicated that several factors (ie, the stage of the primary tumor, signs of ORN) can influence the progress of ORN.
  • [MeSH-minor] Adult. Aged. Debridement. Female. Fractures, Spontaneous / etiology. Humans. Hyperbaric Oxygenation. Male. Mandibular Fractures / etiology. Middle Aged. Neoplasm Staging. Oral Hygiene. Radiotherapy Dosage. Retrospective Studies. Risk Factors. Smoking. Surgical Flaps. Tooth Extraction / adverse effects. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531406.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D: ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res; 2006 Aug 1;66(15):7473-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme is the most common and lethal form of primary brain cancer.
  • In fact, ectopic expression of the orphan RTK ROS is a frequent event in human brain cancers, yet the pathologic significance of this expression remains undetermined.
  • Here, we show that a glioblastoma-associated, ligand-independent rearrangement product of ROS (FIG-ROS) cooperates with loss of the tumor suppressor gene locus Ink4a;Arf to produce glioblastomas in the mouse.
  • We show that this FIG-ROS-mediated tumor formation in vivo parallels the activation of the tyrosine phosphatase SH2 domain-containing phosphatase-2 (SHP-2) and a phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling axis in tumors and tumor-derived cell lines.
  • We have established a fully penetrant preclinical model for adult onset of glioblastoma multiforme in keeping with major genetic events observed in the human disease.
  • These findings provide novel and important insights into the role of ROS and SHP-2 function in solid tumor biology and set the stage for preclinical testing of targeted therapeutic approaches.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinases / metabolism. Protein-Tyrosine Kinases / metabolism. Proto-Oncogene Proteins / metabolism
  • [MeSH-minor] Animals. Astrocytoma / enzymology. Astrocytoma / metabolism. Astrocytoma / pathology. Cyclin-Dependent Kinase Inhibitor p16 / deficiency. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Enzyme Activation. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Protein Phosphatase 2. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Recombinant Fusion Proteins / biosynthesis. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. SH2 Domain-Containing Protein Tyrosine Phosphatases. Signal Transduction. TOR Serine-Threonine Kinases. Tumor Suppressor Protein p14ARF / deficiency. Tumor Suppressor Protein p14ARF / genetics. src Homology Domains

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885344.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 042063; United States / NIGMS NIH HHS / GM / R01 GM 060594
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Protein p14ARF; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ROS1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptpn11 protein, mouse; EC 3.1.3.48 / SH2 Domain-Containing Protein Tyrosine Phosphatases
  •  go-up   go-down


79. Kishi K, Homma S, Takaya H, Miyamoto A, Sakamoto S, Kurosaki A, Motoi N, Yoshimura K: [A clinical study of advanced large cell neuroendocrine carcinoma]. Nihon Kokyuki Gakkai Zasshi; 2006 Aug;44(8):556-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the clinical manifestations, tumor markers, and treatment of these patients.
  • As for tumor markers, the levels of progastrin-releasing peptide (proGRP) and neuron-specific enolase (NSE) were elevated in six patients (67%) and five patients (56%), respectively.
  • The diagnosis of LCNEC was made based on the resected specimens in 8 patients including resection of brain metastasis in 1 and CT-guided needle biopsy in 1.
  • One patient was stage IIIA, 1 was stage IIIB, 3 were stage IV, and 4 had postoperative recurrence.
  • Treatment included chemotherapy alone in 7 patients, chemotherapy plus whole brain radiation in 1, and postoperative radiotherapy in 1.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972612.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin
  •  go-up   go-down


80. Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, Osada S, Ichikawa Y, Shimada H: Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol; 2008 Dec;15(12):3433-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All patients underwent potentially curative resection for CRC without distant metastasis, classified as stage I, II, or III.
  • Multivariate analysis identified tumor-node-metastasis (TNM) stage and preoperative serum CEA level as independent predictive factors of recurrence.
  • The relapse-free survival between CEA levels >10 ng/ml and <10 ng/ml significantly differed in patients with stage II and III.
  • However, there was no significant difference in relapse-free survival between CEA levels >10 ng/ml and <10 ng/ml in patients with stage I.
  • CONCLUSION: Preoperative serum CEA is a reliable predictive factor of recurrence after curative surgery in CRC patients and a useful indicator of the optimal treatment after resection, particularly for cases classified as stage II or stage III.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis. Preoperative Care
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / blood. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Brain Neoplasms / blood. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Female. Humans. Liver Neoplasms / blood. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / blood. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846401.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


81. Hristova M, Aloe L: Metabolic syndrome--neurotrophic hypothesis. Med Hypotheses; 2006;66(3):545-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the early stage of the metabolic syndrome we established a statistically significant increase in the plasma levels of the nerve growth factor.
  • In the generalized stage the plasma levels of the neutrophines were statistically decreased in comparison to those in the healthy controls.
  • We consider that the neurotrophin deficit is likely to play a significant pathogenic role in the development of the metabolic anthropometric and vascular manifestations of the generalized stage of MetSyn.
  • (1) increased tissue and plasma levels of proinflammatory cytokines Interleukin-1(IL-1), Interleukin-6 (IL-6 ) and tumor necrosis factor - alpha (TNF-alpha) caused by inflammatory and/or emotional distress;.
  • [MeSH-minor] Adult. Brain-Derived Neurotrophic Factor / metabolism. Humans. Inflammation. Interleukin-6 / metabolism. Lipid Metabolism. Middle Aged. Models, Biological. Models, Theoretical. Nerve Growth Factor / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Metabolic Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Hypotheses. 2006;67(1):195-6 [16545915.001]
  • (PMID = 16298496.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9061-61-4 / Nerve Growth Factor
  •  go-up   go-down


82. Albornoz V, Mendoza-Topaz C, Oliva C, Tello J, Olguín P, Sierralta J: Temporal and spatial expression of Drosophila DLGS97 during neural development. Gene Expr Patterns; 2008 Jul;8(6):443-51
FlyBase. FlyBase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we present the temporal and spatial expression pattern of DLGS97 during embryonic and larval nervous system development, during eye development and in adult brain.
  • Our results show that DLGS97 is expressed zygotically, in neurons in the embryo, larvae and adult, and is absent at all stages in glial cells.
  • In the brain, DLGS97 is expressed in the mushroom bodies and optic lobes at larval and adult stages; and in the antennal lobe in the adult stage.
  • [MeSH-minor] Alternative Splicing. Animals. Brain / growth & development. Brain / metabolism. Drosophila / embryology. Drosophila / growth & development. Drosophila / metabolism. Embryo, Nonmammalian / metabolism. Photoreceptor Cells, Invertebrate / embryology. Photoreceptor Cells, Invertebrate / metabolism. RNA, Messenger / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501681.001).
  • [ISSN] 1567-133X
  • [Journal-full-title] Gene expression patterns : GEP
  • [ISO-abbreviation] Gene Expr. Patterns
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 143513-41-1 / discs large 1 protein, Drosophila
  •  go-up   go-down


83. Inoue T, Ogasawara K, Kumabe T, Jokura H, Watanabe M, Ogawa A: Minute glioma identified by 3.0 Tesla magnetic resonance spectroscopy--case report. Neurol Med Chir (Tokyo); 2005 Feb;45(2):108-11
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 33-year-old man presented with a minute tumor incidentally detected by magnetic resonance (MR) imaging screening.
  • 1.5 Tesla MR spectroscopy indicated normal brain tissue whereas 3.0 Tesla MR spectroscopy indicated neoplasm.
  • The tumor was completely resected.
  • 3.0 Tesla MR spectroscopy can establish the diagnosis in the early stage of glioma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722611.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


84. Schlamann M, Loquai C, Goericke S, Forsting M, Wanke I: [Cerebral MRI in neurological asymptomatic patients with malignant melanoma]. Rofo; 2008 Feb;180(2):143-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sufficient imaging of the brain is particularly important.
  • Therefore, we explored the incidence of cerebral metastasis in our patient population in relation to the stage of disease to estimate the reasonability of this examination.
  • The incidence of brain metastasis was evaluated.
  • The type of melanoma, the thickness of the tumor, the Clark level, the location of the primary tumor, and the clinical stage were recorded from the clinical records.
  • RESULTS: 15 (12.5 %) of the 120 patients (clinical stage I: 27 patients, stage II: 29 patients, stage III: 25 patients, stage IV: 39 patients) had cerebral metastasis in MRI.
  • 14 patients were in stage III or IV at this time.
  • Consequently 21.8 % of the patients in stage III and IV had cerebral metastasis.
  • Only one patient in stage IIc had cerebral metastasis.
  • CONCLUSION: Cranial MRI of neurologically asymptomatic patients seems to be an important factor in the staging of melanoma especially in the advanced stage of this disease and in patients with a thick primary tumor.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Magnetic Resonance Imaging / methods. Melanoma / diagnosis. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Nervous System Diseases / diagnosis. Nervous System Diseases / etiology. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098094.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, Aldape K: Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res; 2008 Dec 1;14(23):7832-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Paired primary and metastatic tumor samples were obtained from 41 patients who had undergone resection of both primary lung adenocarcinoma and brain metastatic lesions.
  • In multivariable analysis, p-S6 expression was a negative independent predictor of metastasis-free survival after adjustment for tumor stage.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2700-9 [10561344.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):710-7 [16467080.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Eur Respir J. 2001 Oct;18(4):705-19 [11716177.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1216-24 [12128123.001]
  • [Cites] Cell. 2002 Oct 4;111(1):9-12 [12372295.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):193-5 [12562233.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Feb;4(2):117-26 [12563289.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1070-6 [12631609.001]
  • [Cites] Respir Res. 2002;3:27 [12537604.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):597-604 [12827614.001]
  • [Cites] J Korean Med Sci. 2003 Aug;18(4):494-500 [12923324.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):3-7 [14745718.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):430-9 [14739904.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3935-41 [16818690.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):321-8 [17265080.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2257-67 [17440983.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):157-64 [15363541.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Chest. 1992 Apr;101(4):1013-8 [1313349.001]
  • [Cites] BMJ. 1992 Feb 29;304(6826):541-3 [1313719.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1530-7 [15735128.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;65:101-27 [11008486.001]
  • (PMID = 19047111.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-040007; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-040007; United States / NCI NIH HHS / CA / P50CA70907
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / DNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / TTF1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS83486; NLM/ PMC2614348
  •  go-up   go-down


86. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • Adjuvant chemotherapy with carboplatin and paclitaxel was prescribed postoperatively, but the malignancy was not controlled due to lung, brain and vulva metastases.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / secondary. Carcinoembryonic Antigen / metabolism. Combined Modality Therapy. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Necrosis. Vulvar Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


87. Chen X, Li J, Wu K, Han Y, Xu P: Tra2alpha promotes RA induced neural differentiation of P19 cells. Neurochem Res; 2005 Feb;30(2):271-5
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study demonstrates a high level of the nuclear Transformer 2alpha (Tra2alpha) protein in adult mouse brain relative to other tissues, including muscle, heart, liver, lungs, kidney and small intestine, suggesting the potential importance of Tra2alpha in neural function.
  • The level of Tra2alpha in mouse cerebrum is developmentally regulated, peaking at neonate stage.
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Mice. Mice, Inbred BALB C. Signal Transduction / drug effects. Telencephalon / drug effects. Telencephalon / metabolism. Transfection. Tubulin / metabolism. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15895831.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA-Binding Proteins; 0 / Tra2alpha protein, mouse; 0 / Tubulin; 5688UTC01R / Tretinoin
  •  go-up   go-down


88. Maes L, Kalala JP, Cornelissen M, de Ridder L: Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif; 2007 Feb;40(1):14-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By verifying the proliferation capacity, human telomerase reverse transcriptase (hTERT) expression and in vitro invasion, in a group of highly malignant glioblastomas, benign meningiomas and astrocytomas, at the initial stage of progression, we have analysed putative progression in vitro for proliferation and telomerase expression.
  • CONCLUSIONS: The elevated expression of hTERT and Ki-67 in vitro provides a potential prognostic tool for early detection of the progression of brain tumours.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Proliferation. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Telomerase / analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227292.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


89. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J: High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell; 2007 Feb;11(2):147-60
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TGFbeta acts as a tumor suppressor in normal epithelial cells and early-stage tumors and becomes an oncogenic factor in advanced tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Infant. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphorylation. Prognosis. Receptors, Transforming Growth Factor beta / metabolism. Signal Transduction. Smad7 Protein / metabolism. Survival Rate. Tumor Cells, Cultured


90. Hishida T, Nagai K, Yoshida J, Nishimura M, Ishii G, Iwasaki M, Nishiwaki Y: Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg; 2006 Apr;131(4):838-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrence resection was performed for the following sites: 16 in the lung, 5 in the brain, 2 in the adrenal gland, and 1 each in the chest wall, stomach, skin, pelvic lymph node, and malar bone.
  • Advanced p-stage (p-stage II and III, n = 14) of the primary tumor was the significant negative prognostic factor.
  • Patients with p-stage II or III had survival equivalent to that of those who had multiple recurrences or were unfit for further surgical intervention.
  • However, surgical resection might be contraindicated if the primary tumor is stage II or III.
  • [MeSH-minor] Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / secondary. Adult. Aged. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580442.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Wang ZX, Chen YY, Li BA, Tan GW, Liu XY, Shen SH, Zhu HW, Wang HD: Decreased pygopus 2 expression suppresses glioblastoma U251 cell growth. J Neurooncol; 2010 Oct;100(1):31-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results demonstrated that tumor grade exhibited a positive correlation with overexpression of Pygo2.
  • Results showed that inhibition of Pygo2 expression resulted in inhibited cell proliferation and invasiveness, as well as increased cell cycle arrest at the G(1) stage and decreased expression of the Wnt target gene cyclin D1.
  • [MeSH-major] Brain Neoplasms / metabolism. Down-Regulation / physiology. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. RNA, Small Interfering / pharmacology
  • [MeSH-minor] Adult. Analysis of Variance. Bromodeoxyuridine. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Cyclin D / metabolism. Female. Flow Cytometry. Humans. Indoles. Male. Middle Aged. Time Factors. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20204459.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Indoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / PYGO2 protein, human; 0 / RNA, Small Interfering; 0 / beta Catenin; 47165-04-8 / DAPI; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


92. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY: Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer; 2008 Feb;59(2):270-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 35-year-old woman was diagnosed with stage IV non-small cell lung cancer with brain metastasis.
  • With an object of controlling the increased intracranial pressure, we initially performed a craniotomy with tumor removal, followed by whole brain irradiation.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Brain Neoplasms / radiography. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Diagnosis, Differential. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Immunosuppressive Agents / therapeutic use. Infant, Newborn. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Pregnancy Trimester, First. Pregnancy Trimester, Second. Radiation-Sensitizing Agents. Ribonucleotide Reductases / antagonists & inhibitors. Tomography, X-Ray Computed


93. Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin-Chesa P: Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun; 2006;6:10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis.
  • Endosialin is a C-type lectin-like cell surface receptor of unknown function, with a distinctive pattern of endothelial expression in newly formed blood vessels in human cancers.
  • To advance these studies we have generated an antibody to the extracellular domain of mouse endosialin and mapped protein expression from embryonic day E10.0 to the adult stage, complemented by mRNA quantification and co-typing for standard endothelial markers.
  • First, endosialin protein is restricted to vascular endothelium and fibroblast-like cells in developing organs, and largely disappears in the adult.
  • For instance, in the E10.0 embryo, endosialin is prominent in the endothelium of the dorsal aorta and, from E11.0 to E14.5, in vessels sprouting from the dorsal aorta, in perineural vascular plexuses, and in brain capillaries.
  • The endosialin protein persists in the stromal fibroblasts of the adult uterus.
  • Finally, in subcutaneous cancer xenograft models endosialin re-appears in the host-derived tumor stroma, both in neo-angiogenic vascular endothelium and in activated stromal fibroblasts.
  • [MeSH-minor] Animals. Animals, Newborn. Antibodies / metabolism. Embryonic Development. Immunohistochemistry. Mice. Mice, Inbred C57BL. Tumor Cells, Cultured

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875435.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / Neoplasm Proteins; 0 / tumor endothelial marker 1, mouse
  •  go-up   go-down


94. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, Kim HK, Hong EK, Lee JS: Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res; 2005 Apr 15;11(8):3032-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy.
  • EXPERIMENTAL DESIGN: Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions.
  • Of 10 patients with evaluable brain metastases, 7 had objective responses in both intracranial and extracranial lesions, 1 had stable disease in the brain and dramatic response in the extracranial lesions, and 2 had progressive disease in both sites.
  • CONCLUSIONS: Gefitinib showed very dramatic antitumor activity, even in the brain, with unprecedented survival outcome in never-smoker adenocarcinoma patients.
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / prevention & control. Brain Neoplasms / secondary. Disease Progression. Exanthema / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Skin Diseases / chemically induced. Smoking. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


95. Yanada S, Ito H, Tomita M, Wada T, Hatano T, Kishimoto K, Egawa S: [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. Hinyokika Kiyo; 2008 Jan;54(1):43-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological diagnosis was a mixed type nonseminomatous germ cell tumor.
  • We diagnosed him as having stage I testicular cancer and decided to forgo adjuvant therapy.
  • After 8 months of follow-up, he was admitted to our department because of brain, lung, and spleen metastases.
  • Then, two cycles of chemotherapy with paclitaxel, ifosfamide and cisplatin were administered as salvage chemotherapy, which led to a normalization of the serum AFP level, and disappearance of the brain and spleen metastases.
  • Residual lung mass was resected at the surgical department, and microscopically no viable tumor cells remained.
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / secondary. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Lung Neoplasms / secondary. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Salvage Therapy. Splenic Neoplasms / secondary. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Testicular cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260360.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / alpha-Fetoproteins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


96. Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK: MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer; 2007 Apr;48(4):403-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This epigenetic modification has been associated with a favorable prognosis in adult patients with glioblastoma (GBM) who receive temozolomide and other alkylating agents.
  • The methylation status of the MGMT was determined using a 2-stage methylation specific PCR analysis on DNA extracted from tumor specimens which had been snap frozen at surgery.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Brain Neoplasms / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / analogs & derivatives. Glioblastoma / genetics. Neoplasm Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor / drug effects. Child. Child, Preschool. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Drug Resistance, Neoplasm. Etoposide / administration & dosage. Gene Silencing. Humans. Kaplan-Meier Estimate. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609952.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


97. Shen A, Wang Y, Zhao Y, Zou L, Sun L, Cheng C: Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery; 2009 Jul;65(1):153-9; discussion 159-60
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Gliomas are the most common type of primary intracranial tumor.
  • Although tumor grade predicts the clinical course of most patients, molecular characteristics of individual tumors have emerged as important prognostic factors for patients with gliomas.
  • This study assessed whether CRM1, Ser10-phosphorylated p27, and p27 correlated with each other, with glioma pathological stage, and with patient outcome.
  • METHODS: Immunohistochemical and Western blot analysis were performed in 70 cases of human gliomas and normal brain tissues.
  • [MeSH-major] Brain Neoplasms / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Gene Expression Regulation, Neoplastic. Glioma / metabolism. Karyopherins / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Multivariate Analysis. Prognosis. Retrospective Studies. Serine / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574837.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Karyopherins; 0 / Ki-67 Antigen; 0 / Receptors, Cytoplasmic and Nuclear; 0 / exportin 1 protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 452VLY9402 / Serine
  •  go-up   go-down


98. Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A: Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH. Onkologie; 2008 Jul;31(7):380-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The medical records of 105 AJCC (American Joint Committee on Cancer) stage IV melanoma patients from 1994 to 2001 were analyzed retrospectively.
  • In univariate analysis, pre-therapeutic LDH and S100B levels in serum samples (p = 0.01 and p = 0.002, respectively), tumor stage (AJCC IVa-IVc, p = 0.005), and response to the firstline therapy (p < 0.001) were found to be significant prognostic markers.
  • However, in the multivariate analysis, pre-therapeutic S100B serum levels (p = 0.005, odds ratio (OR): 2.22, confidence interval (CI): 1.22-4.1) as well as presence of brain metastases (p = 0.009, OR: 5.08, CI: 1.51-17.05) were the only independent prognostic factors for overall survival.
  • [MeSH-major] Biomarkers, Tumor / blood. Nerve Growth Factors / blood. Risk Assessment / methods. S100 Proteins / blood. Skin Neoplasms / blood. Skin Neoplasms / mortality. Survival Analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Germany / epidemiology. Humans. Longitudinal Studies. Male. Middle Aged. Prognosis. Reproducibility of Results. Risk Factors. S100 Calcium Binding Protein beta Subunit. Sensitivity and Specificity. Survival Rate

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18596385.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nerve Growth Factors; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / S100B protein, human
  •  go-up   go-down


99. Cui X, Wu R, Zhou M, Dong W, Ulloa L, Yang H, Wang H, Tracey KJ, Simms HH, Wang P: Adrenomedullin and its binding protein attenuate the proinflammatory response after hemorrhage. Crit Care Med; 2005 Feb;33(2):391-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The neuroendocrine response to hemorrhage is to maintain perfusion to the heart and brain, often at the expense of other organ systems.
  • We have recently shown that administration of adrenomedullin (AM, a potent vasodilator peptide) and adrenomedullin binding protein-1 (AMBP-1) prevented the transition from the hyperdynamic to the hypodynamic stage in the progression of sepsis.
  • SUBJECTS: Male adult rats.
  • Blood samples were collected 4 hrs postresuscitation and assayed for levels of liver enzymes (i.e., alanine aminotransferase and aspartate aminotransferase), lactate, creatinine, proinflammatory cytokines tumor necrosis factor and high mobility group box 1, and anti-inflammatory cytokine interleukin-10.
  • The results indicate that levels of alanine aminotransferase, aspartate aminotransferase, creatinine, lactate, tumor necrosis factor, and high mobility group box 1 markedly elevated after hemorrhage and resuscitation, and AM/AMBP-1 treatment significantly attenuated these increases.
  • CONCLUSION: The combined administration of AM and AMBP-1 effectively suppresses hemorrhage-elicited organ injury and reduces hemorrhage-induced mortality, partly through down-regulation of proinflammatory cytokines (tumor necrosis factor and high mobility group box 1) and up-regulation of the anti-inflammatory cytokine interleukin-10.
  • [MeSH-minor] Adrenomedullin. Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Creatinine / metabolism. HMGB Proteins / metabolism. Interleukin-10 / metabolism. Lactic Acid / blood. Male. Rats. Rats, Sprague-Dawley. Resuscitation. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699844.001).
  • [ISSN] 0090-3493
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM057468; United States / NHLBI NIH HHS / HL / R01 HL076179
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGB Proteins; 0 / Inflammation Mediators; 0 / Peptides; 0 / Tumor Necrosis Factor-alpha; 0 / Vasodilator Agents; 0 / adrenomedullin-binding protein 1, human; 0 / complement factor H, human; 130068-27-8 / Interleukin-10; 148498-78-6 / Adrenomedullin; 33X04XA5AT / Lactic Acid; 80295-65-4 / Complement Factor H; AYI8EX34EU / Creatinine; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


100. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M: Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol; 2005 Nov;20(11):1781-7
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients with extrahepatic metastases had more advanced intrahepatic tumors at the first diagnosis of HCC: 73.8% of the patients with extrahepatic metastases had tumors of intrahepatic tumor stage T3 or T4 according to the TNM classification, while only 28.5% of the patients without extrahepatic metastases had tumors of T3 or T4 (P < 0.001).
  • Other metastatic sites were the adrenal gland, peritoneum, skin, brain and muscle.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / complications. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Brain Neoplasms / complications. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Disease Progression. Female. Hepatitis, Viral, Human. Humans. Lung Neoplasms / complications. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 16246200.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down






Advertisement